

Progress in Biomedical Engineering



TOPICAL REVIEW

OPEN ACCESS

RECEIVED

14 March 2023

REVISED

19 July 2023

ACCEPTED FOR PUBLICATION

11 August 2023

PUBLISHED

25 August 2023

Original content from this work may be used under the terms of the [Creative Commons Attribution 4.0 licence](https://creativecommons.org/licenses/by/4.0/).

Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.



Updates on polyurethane and its multifunctional applications in biomedical engineering

Zahra Miri¹, Silvia Farè² , Qianli Ma³  and Håvard J Haugen^{3,*} 

¹ Faculty of Medicine and Health Technology, Tampere University, Tampere 33100, Finland

² Department of Chemistry, Materials and Chemical Engineering 'G. Natta', Politecnico di Milano, Milan, Italy

³ Department of Biomaterials, Institute of Clinical Dentistry, Faculty of Odontology, University of Oslo, NO-0317 Oslo, Norway

* Author to whom any correspondence should be addressed.

E-mail: h.j.haugen@odont.uio.no

Keywords: polyurethane, biostability, shape memory, drug delivery, tissue engineering, wound healing, degradation


Abstract

Polyurethanes (PUs) have properties that make them promising in biomedical applications. PU is recognized as one of the main families of blood and biocompatible materials. PU plays a vital role in the design of medical devices in various medical fields. The structure of PU contains two segments: soft and hard. Its elastomeric feature is due to its soft segment, and its excellent and high mechanical property is because of its hard segment. It is possible to achieve specific desirable and targeted properties by changing the soft and hard chemical structures and the ratio between them. The many properties of PU each draw the attention of different medical fields. This work reviews PU highlighted properties, such as biodegradability, biostability, shape memory, and improved antibacterial activity. Also, because PU has a variety of applications, this review restricts its focus to PU's prominent applications in tissue engineering, cardiovascular medicine, drug delivery, and wound healing. In addition, it contains a brief review of PU's applications in biosensors and oral administration.

1. Introduction

The polyurethane (PU) story began in the 1930s when it was synthesized by Professor Otto Bayer [1, 2]. In 1958, PU was used as a shell for the breast-prostheses by Pangman. Later, the same year, Mandarino and Salvatore used a PU called ostamer to fix the bone in situ [3, 4]. Since then, PU has been utilized as a biomaterial in medical applications, and some formulations have been designed explicitly for biomedical applications [4]. PU is a broad category of polymers [5] containing urethane groups formed in the reaction between isocyanate (NCO) and alcohol (–OH) [6]. PU has a complex chemical structure that includes a polyol, a diisocyanate, and a chain extender [7]. PU contains other groups depending on the chemical composition, such as urea, esters, ethers, carbonates, and aromatic components [6]. During the PU synthetic process, in addition to the formation of urethane linkages formation, reactions occur that cause the creation of different bonds, such as biuret, allophanate, and isocyanurate or acyl-urea. These bonds can lead to more branching, which affects the whole structure of the polymer in terms of chemical–physical, mechanical properties, and biocompatibility [8].

PU category can be divided as follow: (i) polyester-based PUs: poly(ester urethanes) was an initial generation of PU that was recognized as applicable but found unsuitable for long-term implantation because of the rapid hydrolytic degradation of the soft segment (aliphatic polyester). (ii) Polyether-based PUs: poly(ether urethanes) were then introduced due to their hydrolytic stability [9]. By contrast, observing the failure rate of medical devices that contained the grade of softer PUs revealed that poly(ether urethanes) can be subject to oxidative degradation [9]. (iii) Polycaprolactone-based PUs can be utilized advantageously as medical, solvent-activated, pressure-sensitive adhesives because of their quick crystallization.



(iv) Polybutadiene-based PUs can be synthesized using polybutadiene diols as the soft segment, providing the material with high elasticity and flexibility. (v) Castor oil-based PUs. Castor oil-based PUs can be synthesized using castor oil as the soft segment, which provides the material with excellent flexibility and biocompatibility. These types of PUs can also exhibit excellent biodegradability, making them ideal for use in applications where a biodegradable material is desired. The last two types are limited to medical applications [8].

PUs can be synthesized into various classes based on their properties, such as flexibility, rigidity, thermoplasticity, binders, waterborne, adhesives, coating, elastomers, and sealants [6]. Meanwhile, PU has been recognized as versatile for applications in different fields. In recent years, PU has become necessary as a biocompatible polymer with superior mechanical properties because of the development and use of biomaterials in tissue engineering (TE). This review aimed to collect updated narrative investigations into PU's critical properties and biomedical applications. Figure 1 shows semi-crystalline polymer and PU structures in linear and foam structures.

2. Polyurethane properties

PU is a polymer composed of repeating units of diisocyanates and polyalcohols. It is known for its versatility and can be used in many applications due to its unique properties, such as high tear strength, good flexibility at low temperatures, low water absorption, and load-bearing capacity. PU has two critical segments in its structure: soft and hard segments. Together, these segments give rise to a versatile structure [12].

The soft and hard segments contain polyhydroxyl and polyisocyanate components [12]. The soft segments are based on long-chain diol, which provides the PU's elasticity [2]. Conversely, the hard segment depends on the low-weight diol, chain extender, and diisocyanate, producing hydrogen bonding containing urethane links and providing extra strength. Therefore, the properties of PU can be tailored by varying the ratio of soft segments to hard segments in its structure. The soft segments, typically polyether or polyester polyols, give PU flexibility and resilience. The hard segments, typically made up of diisocyanates, give PU strength and stiffness. By varying the ratio of soft segments to hard segments, PU can have a wide range of properties, from soft and flexible to stiff and rigid [2, 13]. This ability to tailor the properties of PU makes it useful in a wide range of applications, such as in flexible foam, rigid foam, elastomers, coatings, and adhesives. PUs have been used in biostable films in valves, bladders, and implants for their mechanical and flexible properties [5]. Also, because of these essential properties (mechanical and biocompatibility), PU is a good candidate for medical devices, including vascular stents, artificial organs, wound treatment, and more [4]. Poly(ϵ -caprolactone)-based PU (PCL-PU) copolymers [14, 15] and alginate-based PU composites [16] have been investigated for biomedical applications.

Different PU composites have been developed to improve and enhance their properties for additional biomedical applications. This variety can be achieved by combining PU with other polymers, ceramics, and carbon-based materials [17]. PU was applied in cellulose and collagen composition to investigate its application in manufacturing cosmetic masks. PU was selected to provide the required elasticity for this application. Also, the reason for choosing collagen and cellulose was to ensure bioadhesion and mechanical strength, respectively [18]. PUs can be used as a coating because of their properties, such as their versatile mechanical property, excellent abrasion resistance, toughness, low-temperature flexibility, and chemical resistance [19, 20].

As previously briefly introduced, PU can be made from various polyisocyanates and polyalcohols, resulting in different types of PU with different properties depending on their composition. Polyol and isocyanate are the two main chemical reagents for synthesizing PUs. The polyol contains multiple hydroxyl groups ($-OH$) that react with the isocyanate to form the polymer backbone. Isocyanate is a compound containing one or more isocyanate groups ($-NCO$) that react with the polyol's hydroxyl groups to form the polymer's urethane linkages. The specific type of polyol and isocyanate can significantly affect the properties of the resulting PU. The ratio of isocyanate to polyol also affects the properties of the resulting PU (table 1) [21].

2.1. Various types of PU and their properties





Thermoplastic polyurethane (TPU) is a type of PU that can be melted and reshaped multiple times. They have good abrasion resistance, high elasticity, and good chemical resistance. Polyols include di-hydroxyl terminated macroglycols of polyethers, polyesters, and polycarbonates between 1000 and 5000 Da molecular weight. The molecular weight and polyol's structure are significant in PU's mechanical, physical, and chemical properties [26, 27]. TPUs are non-crosslinked polymers typically made by reacting a polyisocyanate with a polyester or polyether polyol, chain extender, and catalyst. The resulting polymer combines hard and soft segments, with the hard segments giving TPU its strength and stiffness and the soft segments giving it flexibility and elasticity. The properties of TPU can be tailored by varying the ratio of hard segments to soft segments and using different polyisocyanates and polyalcohols (figure 2) [28]. These components define the polymer structure. The soft segment determines the elasticity and flexibility of the TPU and is typically a polyetherdiol in light of its hydrolytic stability in biomedical applications [29]. The hard segments consist of an aromatic di-isocyanate, such as MDI, which gives the polymer its thermoplastic attributes.

A low-molecular-weight diol is also used as a chain-extending agent [28]. One of the key features of TPU is its thermoplastic nature, which allows it to be melt-processed and molded in various shapes and forms. When the ratio of soft and hard segments is high, the PU is more deformable and exhibits a rubber-like behaviour. The soft segments in the polymer structure provide flexibility and resilience, allowing the polymer to stretch and recover its original shape without permanent deformation. When the ratio of soft and hard segments is low, the PU is less deformable and exhibits a more complex and rigid behaviour.

The hard segments in the polymer structure provide strength and rigidity, limiting the polymer's ability to stretch. It is worth noting that the ratio of soft segments to hard segments can be adjusted to achieve the desired balance of properties [31, 32]. For example, a PU with an average ratio of soft segments to hard segments can exhibit a balance of flexibility and strength, making it suitable for various applications.

The polymerization of TPU uses aromatic bifunctional reagents diisocyanate (MDI) and a high-molecular-weight polyether-diol. The short chain-extending diol increases the polymer's molecular weight; e.g. Texin 986 uses MDI and a high-molecular-weight polyether-diol [33]. A short chain-extending diol increases the hard segment and the molecular weight of the TPU [34, 35]. In general, thermoplastic polyether-urethanes, which comprise the most implantable materials, have very high tensile strength,

Table 1. Various types of polyurethanes. Typically, the rate of hydrolytic degradation of polyols observes the order: polycarbonate < polyether < polyester [22].

Type of PU	General properties	Structure [6]	References
Thermoplastic polyurethane	Good hydrolytic stability, abrasion properties, suitable mechanical properties with superior chemical resistance, dimensional stability, stiffness, high impact resistance, high strength, and good process ability. Fully biodegradation rate of TPU is still a challenge as the hard segment (isocyanate) is not degradable in various environment conditions	 <p>The diagram shows the chemical structure of a thermoplastic polyurethane (TPU) repeating unit. It consists of a hard segment (urethane group) and a soft segment (ether linkage). The hard segment is represented by a benzene ring attached to a nitrogen atom, which is part of a urethane group. The soft segment is represented by a benzene ring attached to a nitrogen atom, which is part of an ether linkage. The structure is labeled with 'Hard segment', 'Urethane group', 'Soft segment', and 'Chain extender'.</p>	[23]
Poly(ether urethanes)	Excellent mechanical properties, biocompatibility, flexibility, and hydrolytic resistance. A disadvantage is its lower oxidative and thermal stability	 <p>The diagram shows the chemical structure of a poly(ether urethane) repeating unit. It consists of a hard segment (urethane group) and a soft segment (ether linkage). The hard segment is represented by a nitrogen atom attached to a carbonyl group, which is part of a urethane group. The soft segment is represented by a nitrogen atom attached to a carbonyl group, which is part of an ether linkage. The structure is labeled with 'Hard segment', 'Urethane group', and 'Soft segment'.</p>	[24, 25]
Poly(ester urethanes)	They have appropriate mechanical strength and thermal stability; however, they are susceptible to hydrolysis	 <p>The diagram shows the chemical structure of a poly(ester urethane) repeating unit. It consists of a hard segment (urethane group) and a soft segment (ester linkage). The hard segment is represented by a nitrogen atom attached to a carbonyl group, which is part of a urethane group. The soft segment is represented by a nitrogen atom attached to a carbonyl group, which is part of an ester linkage. The structure is labeled with 'Hard segment', 'Urethane group', and 'Soft segment'.</p>	[21]
Poly(carbonate urethanes)	Chemical stability as compared to poly(ether urethanes). polycarbonate-based PUs provide improved mechanical properties, heat and hydrolytic stability compared to polyester and polyether-based PUs. However, long-term <i>in vivo</i> studies indicate susceptibility to enzymatic hydrolysis and oxidative degradation by inflammatory cells	 <p>The diagram shows the chemical structure of a poly(carbonate urethane) repeating unit. It consists of a hard segment (urethane group) and a soft segment (carbonate linkage). The hard segment is represented by a nitrogen atom attached to a carbonyl group, which is part of a urethane group. The soft segment is represented by a nitrogen atom attached to a carbonyl group, which is part of a carbonate linkage. The structure is labeled with 'Hard segment', 'Urethane group', and 'Soft segment'.</p>	[21, 24]




Figure 2. The basic structure of linear thermoplastic polyether-urethanes with hard (MDI) and soft segments (polyether-diol). Reprinted from [30], Copyright (2022), with permission from Elsevier.

Table 2. Biomedical applications of poly-urethanes [49].

Purpose	Examples	References
Polyether-urethane		
Implants	Artificial heart, cardiac pacemaker leads, vascular tube prosthesis, breast implants, membrane for the reconstruction of the meniscus, materials to fix bones, implants for the reconstruction of facial bones	
Materials with membrane properties	Adhesive materials, materials for drug-delivery-systems, inclusion membrane for the fixation of inner organs, dialyses-membrane, filtration of oxygen-adsorption-module, artificial skin	[49]
Auxiliary material	Catheter, cannula, blood sack, wound dressing	
Polycarbonate		
—	Biostable polycarbonate PU is better for vascular prostheses	[50]
—	Coatings for cardiovascular devices	[51]
Polyester		
Foam	Used as a breast prosthesis coating	[52]
—	Polyester PU is suitable for vascular scaffolds	[50]
—	Cardiovascular stents	[53, 54]
Scaffold	As cardiac tissue model	[55]

toughness, abrasion resistance, and resistance to degradation, in addition to biocompatibility, which has sustained their use as biomaterials [36]. The stability of thermoplastic polyether-urethanes depends on the polyol groups used in the synthesis [37]. TPU are suitable for medical devices such as artificial joints, heart valves, and blood vessels. They are also used in coatings for medical implants, such as stents and artificial heart pumps, to reduce thrombosis [38, 39]. TPU can also be used in wound dressings, sutures, and TE applications [40]. Poly(ether urethanes) are used in blood-contacting applications, such as catheters, heart assist pumps and chambers for artificial hearts, vascular prostheses, drug delivery, and pacemaker lead insulation [24, 41, 42].

Poly(ether urethanes) are made from polyether polyols and are known for their excellent resistance to hydrolysis and good flexibility at low temperatures [43].

Poly(ester urethanes) are made from polyester polyols and are known for their good abrasion resistance, high tear strength, and excellent chemical resistance to oils and solvents. However, it is unstable towards enzymes and has a high degradation rate. Therefore, they can be utilized as bioabsorbable polymers [43].

Poly(carbonate urethanes) are made from a combination of polycarbonate and polyester or polyether polyols, known for their high strength, high temperature, and good chemical resistance [44, 45]. PUs are used due to their physiological compatibility, appropriate haemocompatibility, excellent *in vivo* stability over long implant periods, and excellent physical and mechanical properties [8, 46]. Polycarbonate urethanes have displayed significant potential as durable elastomers that remain stable over extended periods. They demonstrate exceptional resistance to processes such as hydrolysis, environmental stress cracking, and oxidation caused by metal ions [47]. Different polyol groups can affect the properties of the resulting material, such as its flexibility, toughness, and thermal stability. The choice of polyol groups can also affect the material's processing conditions and final properties [26, 48]. Table 2 shows the biomedical applications of various TPUs.

It has been shown that polycarbonate-based urethanes have better biostability and biocompatibility than other types of PU (e.g. polyester urethane) for biomedical applications, which were correlated to better and higher stability of polycarbonate's soft segments inside of the body [56]. Zhu *et al* have designed a system containing 4,4'-methylenebis (cyclohexyl isocyanate) (H12MDI), poly(1,6-hexanediol) carbonate diols (PCDL), 1,4-butanediol (BDO) and 1,6-hexamethylene diisocyanate (HDI) to synthesize polycarbonate-based urethanes and evaluated biocompatibility property using platelet adhesion and haemolytic tests. They reported that this composition could be applied as a biomaterial due to its excellent blood biocompatibility [57]. Previous reports showed that polycarbonate-based urethanes have higher biostability and oxidative stability than polyether urethanes, which caused them to be a better replacement for polyether urethanes for biomedical applications [29, 56]. They showed appropriate heat stability, mechanical properties, and hydrolytic stability; however, they are reported to undergo possible enzymatic degradation because of inflammatory cells for long-term *in vivo* investigations [58].

2.2. Evaluation of bioactivity and biocompatibility

Biocompatibility refers to the ability of a material to perform with an appropriate host response in a specific *in vivo* application. In other words, it means that a material does not cause any adverse non-physiological reaction when it comes into contact with living tissue or bodily fluids. As with all biomaterials, PU's biocompatibility can vary depending on the specific application and the type of tissue or fluid with which the material will come into contact. Therefore, biocompatible materials in one application may not be biocompatible in another one [59]. However, cytotoxicity is the minimum requirement for using a PU for medical applications [60]. PU's cytotoxicity has been extensively investigated, including *in vivo* and *in vitro* studies. For example, PU elastomer was previously evaluated for its blood biocompatibility [61, 62]. In another case study, mouse fibroblast cell lines and human saphenous-vein endothelial cells (HSVECs) were used for culture with various commercial PUs. The results showed that PU could provide sufficient conditions to colonize patient-derived HSVECs [63]. Since different PUs have been developed, it is vital to understand the relationship between biocompatibility and PU structure. Lyman and Picha reported that the biocompatibility of PUs depends on their configuration and morphology [64, 65].


Moreover, the relationship between soft and hard segments and the blood response has been reported in other investigations. They illustrated that the hard segment is widely thrombogenic [66, 67]. Two reasons were considered for this high thrombogenicity; the first was the high-level crystallinity of polymers, and the second one was that they demonstrate a strong and reasonable hydrogen bond surface. Cooper *et al* stated that surface mobility could be essential in interacting with polymers and biological systems [68]. In the late 1980s, many studies investigated chemical, structural and morphological modification in PUs to confirm their blood biocompatibility. Recently, some surface modifications and synthesis methods, such as grafting, chemical incorporation, and coating techniques, have been developed to increase the blood biocompatibility of PUs [69]. Incorporating and substituting nanoparticles is another way to improve PU biocompatibility [70–72]. In addition to the composition variation, ion beams and plasma techniques have been considered an appropriate way to enhance PU biocompatibility [73].

2.3. Biodegradability and biostability

Biostability refers to the ability of a material to resist degradation by microorganisms, such as bacteria and fungi. Biodegradability, on the other hand, refers to the ability of a material to be broken down by microorganisms over time. Some PU formulations can be biostable, meaning they are generally resistant to degradation by microorganisms (table 3). Certain PUs can be made biodegradable by incorporating biodegradable polyols into the polymer structure. These biodegradable PUs are typically made from polyester polyols modified to include groups that microorganisms can easily break down [74].

The degradation mechanism of biodegradable PUs typically involves the action of enzymes produced by microorganisms. The enzymatic degradation of PU is shown in figure 3. The enzymes break down the PU polymer by attacking the ester bonds in the polyol, causing the polymer to lose its mechanical properties and eventually break down into smaller molecules that microorganisms can further degrade [75]. Figure 4 illustrates PU biodegradation.

It is worth noting that the biodegradation rate of PU polymers is affected by various factors, such as the type of polyol used, the environmental conditions (e.g. temperature, humidity, and the presence of other microorganisms), and the size and shape of the polymer. Therefore, the biodegradability of PU polymers is highly dependent on the specific conditions of the environment. PU can degrade through various mechanisms depending on the type of polyol used. Degradation mechanisms can co-occur, and their degradation rate is affected by environmental conditions. Therefore, choosing the appropriate PU type is



essential depending on the intended application and environmental exposure conditions [10]. Some of the possible degradation mechanisms include:

Ester hydrolysis: PUs made from polyester polyols are vulnerable to hydrolysis, a chemical reaction that occurs when the water breaks down the ester bond in the polyol. Hydrolysis can cause the PU to weaken and lose its mechanical properties over time [10].

Ether oxidation: PUs made from polyether polyols are vulnerable to oxidation, which is a chemical reaction that occurs when the ether bond in the polyol is broken down by oxygen. This can cause the PU to become brittle and lose flexibility over time [76].

Heat-induced oxidation (HIO): is a degradation mechanism that can occur in polyurethanes (PUs) when exposed to high temperatures. HIO can cause the PU to become brittle and lose its mechanical properties, as well as a change in colour and surface appearance. During HIO, the polymeric chains in the PU can break down due to the presence of free radicals generated by the high temperature. This can lead to the formation of short-chain fragments, which can cause crosslinking between the polymer chains. While this crosslinking can increase the PU's thermal stability, it can also cause the material to become brittle and lose its mechanical properties. The brittle behaviour of PUs at high temperatures instead of melting is due to the nature of the polymer structure. PUs typically comprise soft and hard segments, resulting in a complex morphology that can affect the material's behaviour at high temperatures. The hard segment in the PU can act as a stabilizing agent, preventing the material from melting even at high temperatures, but when exposed to HIO, the hard segments can also degrade, causing the material to become brittle. While increasing the temperature can cause crosslinking in PUs, it can also lead to HIO, which can cause the material to become brittle and lose its mechanical properties. Understanding the underlying mechanisms of PU degradation at high temperatures is essential for developing PUs with improved thermal stability and better resistance to HIO [77].

Environmental stress cracking (ESC): is a phenomenon that can occur in PUs when exposed to certain chemicals and mechanical stress. ESC can cause PU to become brittle and lose its mechanical properties, resulting in cracks and failure of the implanted device. ESC is more commonly observed in polyether-based PUs (PEUs) than polyester-based PUs (PESs) due to ether linkages in the polymeric chain. When exposed to




Figure 4. PU biodegradation occurs in two steps via the activity of urethanases and esterases. Reprinted from [98], Copyright (2013), with permission from Elsevier.

certain chemicals, these ether linkages are more susceptible to hydrolysis, forming cracks and fissures in the material. Mechanical stress, such as bending or flexing of the material, can further exacerbate ESC's effects by increasing the crack propagation rate. The synergistic effect of chemical exposure and mechanical stress can cause the PU to fail, leading to potential complications in medical device applications. ESC is a significant concern, as PUs are commonly used in implanted devices such as catheters, stents, and artificial heart valves. In these applications, the PU may be exposed to various chemicals in the body, such as blood, enzymes, and

Table 3. Summary of some development of biostability of PU.

Date	Outcome	References
2009	Poly(carbonate urethane)s have been studied as biostable elastomers for long-term implantable PU biomaterials. Micro-catheters made of poly(carbonate urethane) (Bionate®) and poly(ether urethane) (Pellethane®) were designed and tested to compare their long-term <i>in vivo</i> stability. The PU catheters were stretched and exposed to a hydrogen peroxide/cobalt chloride solution for up to 10 months. The results showed that the soft polycarbonate segment of the PU catheters was more resistant to oxidative degradation than the polyether soft segment. The study suggests that poly(carbonate urethane) could be appropriate for developing long-term implantable biomaterials.	[108]
2013	Silicon-based polyurethanes (PUs) are being investigated to improve the biostability of PUs due to silicon's high resistance to oxidation, temperatures, and water. Silicon-based thermoplastic PU nanocomposites were created using commercial ElastEon™ E5325, which showed improved biostability of the silicon-based PU nanocomposites against metal ion-induced oxidation, suggesting their potential use in long-term implantable biomaterials such as artificial intervertebral discs.	[109]
2012	To improve the biostability of polyether-PU, layered silicates with more excellent chemical resistance than native PU were incorporated. Cloisite® 30B (QACMMT), a commercially available and organically modified montmorillonite, was utilized in the research. QACMMT contains quaternary ammonium compounds (QAC), specifically methyl tallow bis-2-hydroxyethyl ammonium chloride, as an organic modifier. Upon the addition of QACMMT at loadings below 3 wt%, the biostability of the PU increased by up to 50%, primarily due to decreased material permeability.	[110]
2022	Segmented thermoplastic polyurethanes (STPUs) with varying hard-to-soft segment ratios were synthesized and characterized for use in shape memory polymers. Results showed that PUs with higher hard segment content underwent less degradation, with only 4%–5% mass loss for higher hard segment content samples versus 28% mass loss for lower hard segment content samples under 20% H ₂ O ₂ conditions. This suggests that stronger interactions between chains increase material stability and enable the tuning of biostability based on the required degree of degradation.	[111]

medications, which can lead to ESC. In conclusion, ESC is a phenomenon that can occur in PUs, especially in polyether-based PUs when exposed to certain chemicals and mechanical stress. Understanding the underlying mechanisms of ESC is essential for developing PUs with improved chemical and mechanical stress resistance, which can increase the safety and efficacy of implanted medical devices [78].

Enzymatic degradation: PUs are known to be biodegraded by certain microorganisms, particularly bacteria and fungi. Enzymes can cause PU to become weaker and lose its mechanical properties over time [76, 79, 80].

Carbonate degradation: PUs made from polycarbonate polyols are vulnerable to degradation caused by the presence of the carbonate group in the polyol, leading to a loss of strength and mechanical properties [10, 81, 82].

Biostability is another essential property for the long-term medical application of PU [36]. Polyester-based PU is known not to be resistant to hydrolysis. The ester-group starts to degrade after implantation, leading to strong inflammatory reactions. This problem was solved by introducing a hydrolysis-stable polyether-urethane [83] based on polyether. Hence, polyester-based PUs are no longer used to produce implants [36]. Generally, the hydrolytic degradation of polyether-urethanes in pure water is minimal. Nevertheless, the aqueous environment of the body, i.e. cations and anions, has a strong catalytic effect in hydrolysis. Polyether-urethanes and polycarbonate-urethanes are generally less susceptible to hydrolysis than polyester-based ones. However, they can degrade hydrolytically at high temperatures (>50 °C) in the presence of water. These conditions often exist in polymer processing methods like injection molding and extrusion [84] and should be avoided.

For this reason, most PUs available for medical applications are based on polycarbonate or polyether. However, the biodegradation property of PU has been widely investigated [8, 85, 86]. In this regard, some modifications have been reported to improve PU biostability.

One proposed modification is to replace the soft domains in the PU with materials that have improved stability, such as polysiloxane or polyolefins [87–89] since it has been reported that the soft segments had the most prominent effect on biostability [90]. Haugen *et al* found that polyether-urethane scaffold biostability was worsened with a higher gamma-irradiation dose [79, 91]. Cozzens *et al* [88] designed a new PU based on

a mix of poly(tetramethylene oxide) (PTMO)/poly-isobutylene (PIB) and provided accelerated testing (H_2O_2 (20%) solution contained 0.1 (M) CoCl_2 at 50 °C) to evaluate and analyse resistance against degradation of metal ions oxidative *in vivo*. The new composition showed considerable stability compared to the commercial types, like Pellethane 2363-80A and 2363-55D [88].

Additionally, surface modification [92], antioxidants [93], and nanoparticles [94, 95] were also introduced as methods for the improvement of PU stability. Notably, the biostability property is vital for long-term applications since biodegradation entails a loss of shape and mechanical properties. However, investigation of some scaffolds-based biodegradation in PU is also needed in TE, and control of the degradation rate is essential in some applications, such as drug delivery, scaffolds, and short-term implants [96, 97]. Many factors can affect PU's biostability, including mechanical properties, chemical structure, morphology, fabrication methods, and working condition [95]. Surface chemistry, the relative hydrophobicity, and hydrophilicity of polyether-urethanes have been found to influence the proteins adsorbed by the surface [37]. The first event in soft tissue interactions with polyether-urethane is the adsorption of water and protein onto the surface, followed by an acute inflammatory response characterized by polymorphonuclear leukocytes. The consequence of the adsorbed protein layer on the biomaterial is that cells never actually contact the material. After protein adsorption, an acute response is followed by chronic inflammation, which includes a wound-healing mechanism and foreign body reactions involving macrophages and fibroblasts [59]. Like many other biomaterials, polyether-urethanes elicit a foreign body response determined by multinucleated giant cells in contact with their surfaces, generally called ESC.


Additionally, researchers have found that polyether-urethanes often become encapsulated in a fibrous capsule [36, 99]. Ultimately, this influences the subsequent cell migration and implant function [100]. Mohanty *et al* [101] and other researchers [102] have found a relationship between pore size and the infiltration of macrophages into a polymer implant. The researchers found that a 5–10 μm pore inhibits cell infiltration in the bulk material, while larger pore sizes (200–300 μm) encourage cell infiltration [36]. Mohanty's work also indicates that a porous implant delays the incidence of capsule formation and contracture for about ten years. Haugen *et al* reported using porous PU as a gastro application to reduce gastroesophageal reflux diseases. Where Haugen *et al* developed a porous PU implant with supercritical CO_2 [103, 104], where the porous structure was supposed to fixate around the oesophagus. Recently, *in vivo* experiments have shown that tissue ingrowth into a porous PU structure is only possible with plasma surface treatment, and untreated TPU resulted in massive fibrotic encapsulation [105].

Hence, chemical composition is the key factor [86]. ESC is also reported as one reason for PU's degradation [106]. Various works have investigated other mechanisms of PU degradation [5, 9, 97, 107].

In summary, over the last two decades, several chemistry approaches have been designed primarily focusing on decreasing or eliminating functional groups sensitive to oxidative degradation to improve biostable PUs. *in vivo* analysing and animal investigations have produced long-term biostability for clinical applications. While most approaches have helped design PU elastomers with improved resistance to oxidative degradation compared with conventional PU, their utility in long-term medical implants is yet to be assessed. The improved understanding of the relationship between PU chemical structure on properties and biostability will help synthetic polymer chemists design new materials to suit the needs of next-generation medical implants.

2.4. Shape memory property of PU

Smart materials known as shape memory polymers (SMPs) can remarkably alter and regain their shape in response to various stimuli [112]. The shape memory of polymers has been investigated previously [113]. Shape memory polyurethane (SMPU) is a TPU that exhibits shape memory properties. When SMPUs are heated above their glass transition temperature (T_g) but below their melting temperature (T_m), the material can be deformed into a temporary shape maintained by cooling it below the T_g . Soft segments in the PU structure are responsible for this temporary shape, as they allow the material to be deformed and maintain the temporary shape. Upon heating the material above the T_g , the hard segments in the PU structure help to recover the material's permanent shape. The hard segments are responsible for 'remembering' the permanent shape and help drive recovery [114, 115]. T_m is an essential parameter for processing SMPUs to achieve the desired permanent shape. During processing, the material is typically heated to a temperature above the T_m to facilitate the recovery of the permanent shape. The shape memory behaviour is achieved by adjusting the polymer structure's ratio between hard and soft segments. The hard segments provide the polymer with shape memory properties, while the soft segments provide flexibility and elasticity [116]. SMPU can be a good candidate for medical devices because of their flexibility in shape change in different areas [117, 118]. A specific chemical combination can allow a geometric shape-changing that makes them resistant to external



factors like pH [119], light [120], and temperature [121], as shown in figure 5. This change is because the polymer's structure contains switching segments [122]. If the temperature exceeds the glass transition temperature (T_g), materials are in their rubbery-elastic form, which can deform easily in the desired shape. If the temperature falls below T_g , they become fixed without any deformation in shape. At this step, materials are rigid. For biomedical applications, T_g should be around the body temperature to allow the recovery of the permanent shape *in vivo*. This phenomenon occurs due to molecules' movement and structure [117]. This shape memory property can make these polymers an ideal material for medical devices because they can keep a specific shape during implantation or delivery and recover to their original shape. Interestingly, increasing the temperature above T_g can recover the materials' original, permanent shape. The development of SMPUs began 15 years ago [117]. The biomedical applications of PUs as SMPs include clot removal, vascular occlusion, and stenting [123, 124]. Also, it has been reported that SMPs can be used for cardiovascular implants [53], bone tissue engineering (BTE) applications [116], electromagnetic shielding, pressure bandages, and self-healing [125]. Also, range of dual bioactive electroactive shape memory PU elastomers by incorporating dopamine into a formulation has been synthesized based on citric acid, PCL, dopamine, and the electroactive aniline hexamer. These materials are suitable for soft tissue applications that require sensitivity to electrical like skeletal muscle regeneration [126]. A pH-sensitive PU was also designed.

In this case, the shape memory of PU depended on pH variation instead of temperature variation. The mentioned PU was designed for drug delivery and TE applications [127–131]. It is worth noting that the

shape-memory effect is highly dependent on the specific conditions of the environment, such as the temperature, humidity, and the type of polyol used [132]. De Nardo *et al* showed that SMP scaffolds could be obtained via solvent casting/particulate leaching of gelatin microspheres prepared via oil/water emulsion. Varying the gelatin microsphere size enabled easy control of scaffold morphology, pore size, and shape. Homogeneous spherical and interconnected pores have been achieved with the preservation of shape memory ability, with a recovery rate of up to 90%. Regardless of pore dimensions, MG63 osteoblast-like cells were observed adhering and spreading onto the inner surface of the scaffolds obtained in *in vivo* tests [118, 133].

In summary, using SMPUs in various applications demonstrates their versatility and importance. The shape memory effect can be driven by external forces such as electricity, temperature, electricity, and light. SMPs respond to external stimuli because of hard and soft segment domains. Desired properties of SMPUs can be achieved by cross-linking through ionic, covalent, and hydrogen bonding [128].

2.5. The antibacterial property of PU


Some types of PU have been designed to exhibit antibacterial properties. This can be achieved by incorporating antimicrobial agents, such as silver or zinc ions, into the polymer structure. These antimicrobial agents can kill or inhibit the growth of bacteria, fungi, and other microorganisms on the surface of PU devices [136]. The antimicrobial agents are incorporated into the polymer structure during the manufacturing process, and they are released slowly over time, providing long-lasting protection against microorganisms. The antimicrobial agent's release rate can be controlled by adjusting the concentration of the antimicrobial agents in the polymer and the molecular weight of the polymer [137]. Antibacterial PU can be used in many applications where controlling microorganisms' interaction with the PU structure is essential, such as in medical devices and food packaging. Like any other antimicrobial agent, the effectiveness of the antibacterial properties of PU can be influenced by many factors, such as the amount of antimicrobial agent used, the type of microorganism, and the environmental conditions [138]. Therefore, choosing the appropriate type of PU and antimicrobial agent is essential, depending on the intended application and the microorganisms needing control [139].

Kasi *et al* comprehensively collected these investigations. Different methods and materials have been reported to increase antibacterial properties [140]. Moreover, silver (Ag) nanoparticles, metal oxides and metals, nanomaterials based on carbon, synthetic polymeric materials based on PU, natural sources, and more have been reported [140]. In a different study, functionalized PU was applied as a magnesium (Mg) coating to enhance and improve antibacterial and corrosion resistance. The results showed considerable enhancement in corrosion resistance and excellent antibacterial activity [141]. Jiang *et al* designed amphiphilic poly(dimethylsiloxane) based on PUs, using carboxybetaine to obtain an antibacterial effectiveness of 97.7% [142]. Because PUs have remarkable properties, they have been used as a based substrate for other antibacterial agents, such as copper oxide (CuO) and chitosan [143, 144]. The effects of different agents, such as Ag, zinc oxide (ZnO) [145], and titanium dioxide (TiO₂) nanoparticles loaded in a PU matrix, have been reviewed, and it has been reported that these nanoparticles can improve PUs' antibacterial activity [146]. Wang *et al* reviewed the antimicrobial PU coatings for different applications [147]. Also, Wang *et al* evaluated the antibacterial activity of PU and suggested different methods to design PUs' antibacterial properties for use in medical devices [136].


3. pH-responsive PUs

pH-responsive PUs are a type of PU that can change their properties in response to environmental pH changes. These PUs have pH-sensitive groups incorporated into their polymer backbone, which can respond to changes in pH by changing their conformation [148]. This can lead to changes in solubility, swelling, and mechanical properties. pH-responsive PUs have been investigated for many applications, such as drug delivery and TE [12]. In TE, pH-responsive PUs can mimic the natural pH changes in the body, such as in the stomach or gut. These PUs can be used to produce scaffolds that can change their properties in response to changes in pH, promoting cell growth and differentiation [149]. The properties of pH-responsive PUs can be tailored to specific applications by adjusting the pH-sensitive groups in the polymer structure and the pH range at which the PU will respond. For example, pH-responsive PUs can be used to control the release of drugs by changing their solubility at different pH levels [148]. In a neutral environment, the PU is insoluble, and the drug is not released, while in an acidic environment, the PU becomes more soluble and the drug can be released. pH-responsive PUs can be categorized into different fields, including (i) optical imaging, (ii) drug delivery, (iii) bioactuators and biosensors.

pH-responsive PUs can provide a substrate for controlling targeted drug delivery and the release rate [150, 151]. pH-responsive PUs have primarily been investigated because of their optimal mechanical



properties [152], easy synthesis [153], possible biodegradability, and biocompatibility. Most pH-responsive PUs for controlled and targeted drug delivery are based on crosslinked networks, like hydrogels and microgels. Notably, the hydrogel has a porous structure and can swell in water. The most-used polymers in this application are redox and dual pH-responsive PUs that maintain either ketal or disulfide crosslinkers. This structure can help release drugs in a controlled acid-type pH and protect them from the drugs (figures 6 and 7) [12]. Also, the nano-gels have a diselenide crosslink in their structure, granting excellent colloidal stability. The drug loading efficiency of 76.3% has been reported for nano-gels by Cheng *et al* [154]. Moreover, the compact structure of nano-gels in the core prevents the leakage of drugs. Since they can swell, they could accelerate the release process in the presence of pH 5.0 and a high concentration of H_2O_5 [12, 154]. Song *et al* designed a nanomicelle based on PU that contained some soft chains, including hydrophilic



PEG, poly(neopentyl glycol adipate) diol (PNA-2000), 2-[*N,N*-bis (2-hydroxyethyl)] aminoethanesulfonic acid sodium salt (BES-Na) and 1,4-butanediol (BDO). Folic acid was embedded in micelles, and PU micelles were self-assembled, improving the micellar's stability. The results showed that the drug release was greater in an acidic environment compared with pH 7.4 [155]. The delivery of doxorubicin (DOX) loaded on responsive PU micelles occurred at pH 5.5, and less toxicity was observed in an *in vivo* environment [156].

Another application of PU is in cancer therapy [148]. Tumours tend to grow in an acidic environment. The pH value of the bloodstream is about 7.4; however, the pH of the existing tumoural cells and the components of the endocytic cells is from 4 to 6. This difference makes it necessary to provide pH-targeted drug delivery systems. As a result, utilizing pH-sensitive biodegradable PU nanoparticles as a carrier for the delivery of anticancer drugs has been analysed both *in vivo* and *in vivo* with promising results [157].

While pH-responsive PUs have the potential for a wide range of applications, some drawbacks are associated with their use [158]. Some of the main drawbacks are briefly described here below.

- (1) **Limited pH range:** pH-responsive PUs typically have a limited pH range to respond. pH range can make it challenging to achieve the desired response over a wide range of pH conditions;
- (2) **Inconsistent response:** pH-responsive PUs can have an inconsistent response to changes in pH. The response can make it challenging to achieve a consistent and predictable release of drugs or to achieve consistent cell growth and differentiation on the scaffold;
- (3) **Complex synthesis:** Synthesis of pH-responsive PUs can be complex and challenging, requiring a high degree of control over the polymerization process [159],
- (4) **Cost:** The cost of pH-responsive PUs can be higher than conventional PUs due to the complexity of the synthesis process and the need for specialized equipment;
- (5) **Toxicity:** Some pH-sensitive groups used in pH-responsive PUs can be toxic to cells and negatively affect PU performance [159].

It is worth noting that pH-responsive PUs are still under development, and ongoing research aims to address these drawbacks and improve their performance and applicability in various fields [158].

In conclusion, pH-responsive PUs attracts attention in the pharmaceutical and biomedical industries. Although there is great potential in biomedical and drug delivery systems, such attempt is still needed to confirm their safety and effectiveness in biological systems. It seems that in most investigation on pH-responsive PU systems for biomedical and drug delivery applications, the stability, biodegradability, biocompatibility, and mechanical properties of the PU as the potential polymeric substrate for various potential drug delivery and biomaterials were not compared with other polymeric materials in more details. Therefore, *in vitro* and *in vivo* studies of pH-responsive PUs should be conducted more to guarantee the safety of PUs in *in vivo* environments for further clinical usage [12].

4. PUs as medical devices

PUs have been used as a material for various medical devices due to their unique properties, such as biocompatibility, flexibility, strength, and durability [160]. Some examples of medical devices made from PUs include [161] the following ones:




Figure 8. Trileaflet PU valves developed by the Aachen group. (a) The Reul-Ghista trileaflet valve, (b) the Reul-Häussinger valve, and (c) the Helmholtz Institute valve. [172, 2011], reprinted by permission of the publisher (Taylor & Francis Ltd, www.tandfonline.com).

Surgical implants: PU can make artificial joints, such as spinal discs, heart valves, and other surgical implants. Some examples of PU valves are shown in figure 8. The flexibility and strength of PU make it an ideal material for these applications, as it can withstand high fatigue resistance and provide a long service life [162, 163].

Catheters: PU can make catheters, which are thin, flexible tubes to remove bodily fluids or deliver drugs or other biomolecules. The flexibility and durability of some PUs make them ideal for catheters, as they can bend and twist without breaking and withstand repeated use [164].

Stents are small, mesh-like tubes with open, blocked or narrowed blood vessels. However, due to PU's appropriate flexibility and durability, examples of PU are ureteral stents commonly used in urologic disorders aiding urine flow [165, 166].


Wound dressings: PU can be used to make wound dressings that can protect and promote the healing of skin wounds, and the PU properties allow for conforming to the shape of the wound without breaking [167].

Artificial skin and tissue engineering (TE): PU's biocompatibility and flexibility can also be used for artificial skin and TE. It can be used to make scaffolds for TE and can be used to mimic the mechanical properties of natural skin.

It is worth noting that the medical use of PU requires rigorous testing and CE/FDA approval, as the safety and efficacy of the medical device are of paramount importance [168].

Cardiovascular disease is one of the leading causes of mortality worldwide. Heart valve replacements and cardiovascular procedures have recently increased [169, 170]. It has been reported that 82.6 million elderly people in the United States suffer from cardiovascular disease [169]. Autologous arteries and veins or vascular grafts (Dacron and Goretex), which are biostable, have been applied as prostheses. Synthetic vascular grafts are helpful for large and medium blood vessels, but they are not effective for small types (diameter < 6 mm) because they can cause many thrombotic difficulties [171].

Moreover, they lack sufficient biocompatibility and elastic properties [173]. Cardiac valves based on xenografts and synthetic materials such as ceramics, metals, and polymers have been utilized for many years.



However, these materials are not considered ideal due to concerns regarding their haemocompatibility, long-term mechanical stability, and antithrombogenicity [174]. In light of this, although calcification has been an issue, PU has been recognized as an alternative that can provide good mechanical and biocompatibility properties for cardiovascular applications [118, 119]. PU is extensively investigated for in cardiovascular applications due to its properties of elasticity, high shear strength, durability, light weight, fatigue resistance, transparency, and, importantly, good biocompatibility, tolerance, and acceptance during the treatment and healing process, which allows unrestricted use in blood-contacting devices [175, 176]. PU has been investigated as a possible candidate for a medical device for cardiovascular applications, such as vascular prostheses, heart valves, and cardiac assistance devices. This is because, as mentioned in the previous sections, PU has perfect biocompatibility and blood compatibility [177, 178]. Also, PU has been used as an insulator in the structure of cardiac pacing leads, which are thin wires used to deliver electrical impulses to the heart to treat arrhythmias. However, some degradation problems are associated with using polyether urethanes as an insulator in cardiac pacing leads [110, 172, 179]. Although all components of polyether-urethane, including the soft segment, hard segment, and chain extenders, have the potential to be toxic either by themselves or as part of degradation products, there have not been any published reports linking the use of polyether-urethane implants or the degradation of polyether-urethane to cancer [36].

As PU is a reliable candidate for short-time application, many medical devices based on PU have been developed [180]. Previously, the applicability of PUs for small-diameter vascular applications has been reviewed. These applications can be divided into two different groups: biostable prostheses and biodegradable scaffolds. So, the requirements for these groups' long- and short-term applications are thoroughly explained previously [50].

Insulator failure: PU can degrade over time due to exposure to heat, chemicals, and microorganisms. Such failures can lead to a loss of mechanical properties, such as strength and flexibility, and can affect the performance of the cardiac pacing lead. Insulator failure is a major problem for the pacing leads and can lead to the lead breaking or malfunctioning, which may require replacement surgery.

Fracture: Although PUs have good mechanical properties, haemocompatibility, and biocompatibility, they can become brittle after prolonged mechanical load and can fracture when subject to mechanical stress and degrade during long-term applications [54], resulting in severe problems after implantation. Fractures can lead to a loss of electrical insulation, which can cause electrical leakage and lead improper heart pacing. It has been demonstrated that a coating containing antioxidants on the surface can decrease oxidative degradation [181]. Also, designing a vascular graft based on PU/glycosaminoglycans has shown promising results [182–184]. Moreover, PU-nanofibres are nontoxic materials that can provide an environment and substrate for the human umbilical cord vein endothelial cells [184]. Polymer from a family of degradable-polar hydrophobic ionic polyurethanes (D-PHI) was applied to produce multifunctional thin films based on PU that could prevent blood clotting and decrease the immune system response [185]. PUs' resistance against microbes prevents infection and decreases the risk of rejecting foreign materials [186, 187]. The tensile mechanical properties of different materials have been compared with the native heart tissue to fabricate heart valves. It has been reported that among the compared materials, PU and poly(glycolic acid) (PHA) had remarkable mechanical properties compared to the soft materials (figure 9) [188].

Allergic reactions: Some individuals may be allergic to PU, which can cause inflammation, itching, and other symptoms. This can be particularly problematic for long-term devices such as cardiac pacing leads. Blood biocompatibility is another main criterion restricting biomaterials useful for cardiovascular applications [175, 176]. Various surface modifications have been developed to increase blood biocompatibility. PUs can be subjected to chemical and physical changes. It has been reported that surface modification can change only the physical properties and does not influence bulk chemical properties [186, 189]. Altering the physical surface can enhance the PU's haemocompatibility without compromising its structured surface and bulk properties. This can be achieved through protein adsorption or platelet adhesion on the structured surfaces [190]. Calcification often limits the use of polyether-urethanes in cardiovascular applications [191]. *in vivo* and *in vivo* polyether-urethane calcification has been reported, and they are associated with stiffening, failure in flexure, and perforations [36, 192, 193]. Most of the effects of calcification on polyether-urethanes have been investigated concerning cardiovascular devices [36, 191]. Because PUs are excellent bioinert and biocompatible polymers, they have applications as thromboresistant coatings [194] to prevent blood clot formation [194]. Although PUs have advantages, their disadvantages, such as cost or unexpected effects on the activation of the complement group, should be considered [195]. PUs have also been reported as a substrate for cardiac stem cell treatment [196]. PUs have other cardiovascular applications, such as ventricular-assisting devices and pacemaker leads [110, 175, 197]. Previously, a series of elastomeric films featuring a surface micropattern have developed. These films are made from a combination of poly(glycerol sebacate) (PGS) and graphene (Gr). They exhibit sufficient mechanical strength (0.6 ± 0.1 – 3.2 ± 0.08 MPa) to withstand heartbeats, and the micropatterned structure also aligns with the natural anisotropy of the myocardium in both transverse and vertical orientations. Additionally, the incorporation of Gr enables these films to be conductive (up to 5.80×10^{-7} S m⁻¹), facilitating the conduction of electrical signals between cardiomyocytes and the cardiac tissue. The obtained data showed that electroactive micropatterned anisotropic elastomer film can be used in cardiac TE [198].

Incompatibility with imaging techniques: Polyurethane (PU) can interfere with specific imaging techniques, such as magnetic resonance imaging (MRI), due to the susceptibility of PUs to generate artefacts in the images. PU-based medical devices behave similarly to natural tissue. This can make it difficult to differentiate between the PU and surrounding tissue on imaging scans, leading to image artefacts and reduced diagnostic accuracy. The reasons for this MRI-PU interface are related to the material's magnetic properties, including its susceptibility to magnetic fields, radiofrequency interference, and eddy currents. These properties can lead to image distortion, signal loss, and other artefacts in MRI scans. While PU has numerous advantages for medical devices, its interaction with specific imaging techniques, such as MRI, can lead to imaging artefacts and reduced diagnostic accuracy. As a result, understanding the limitations of PU in imaging can be crucial for developing appropriate medical devices and interpreting diagnostic imaging results [199].

In summary, although studies have reported that PUs suffer from severe problems when applied in blood-contacting devices implanted for long periods, they can be modified regarding chemical composition and surface characteristics to improve their mechanical properties and blood interaction [200]. These modifications enable the use of PUs in the design and manufacture of cardiovascular devices. Heart valves and heart patches among cardiovascular devices need materials with appropriate properties, such as strength and elastomeric mechanical behaviour, to tolerate the cardiac contractile tissue and support regeneration [201]. It is vital to design heart patches and valves to create a structure similar to muscle tissue. PUs are appropriate for cardiac applications because their biocompatibility and elastomeric behaviour enable them to resist cyclic heart stresses without plastic deformation or fatigue failure [1]. The PU structure can be modified to create anisotropic microstructures that may mimic the heart tissue function's varying pore sizes. This could promote cell colonization, cell migration, nutrient supply, and vascularization. However, efforts are still needed to bring PU-based cardiovascular devices to clinical application. More controlled, detailed, and deeper investigation *in vivo* and *in vivo* characterizations are needed to gain PU-based cardiac patches finally, and heart valves approval as medical devices [202].

4.1. PUs for drug delivery

PUs have been investigated as a material for drug delivery systems due to their unique features and have been used as PU-based hydrogels, PU-based nanoparticles, PU-based microparticles, and PU-based films and membranes [203]. For example, they can be used as a coating on implantable devices to control the release of drugs. The properties of PU can be modified to suit the specific drug delivery application by adjusting the polymer properties, such as porosity, mechanical properties, and degradation rate [204]. Controlled drug delivery has been an important issue in recent years because of its advantages, such as lower toxicity and less time required for injection [205, 206]. Also, selecting a carrier for the drug is critical because it can protect

drugs from damage or loss or play an essential role in providing a targeted and smart release [207]. Carriers are applied to immobilize the active materials and substances in drug delivery preparation. They should have a balanced structure between hydrophobicity and hydrophilicity and good biocompatibility [208, 209]. The form of a carrier can vary based on the targeted application [210]. PUs are an attractive material for drug carriers and drug delivery systems because of many possible modifications and processing techniques that can be applied to control drug release systems. PU nanoparticles, scaffolds with various porosity and pore sizes or coatings, different compositions and hydrophilic properties of raw materials, type, and the ratio of hard and soft segments, crystallinity, and the crosslinking degree have the properties and forms that give the possibility to control speed and amount of drug released. Also, modified cross-linked PUs can behave as hydrogels, absorbing large amounts of water without dissolving, an essential quality for drug carriers [207].

Depending on the targeted application of PUs, they can be classified into two groups: biodegradable and bioinert. The first category is used in drug delivery [211]. PU scaffolds or stents have been recognized as a suitable carrier for drug delivery, and many investigations have been conducted. Moon *et al* loaded heparin-deoxycholic acid (DOCA) into a PU coating and reported that the percentage of loaded DOCA on the PU was more than 75% and that the released DOCA could prevent fibrin clot formation or adhesion of platelets on the film and layer surface [212]. Moura *et al* demonstrated the potential for drug delivery using PU-based implants by loading dexamethasone onto the material. Their findings showed that using PU for drug delivery could modulate the fibrosis and angiogenesis induced by the disc-shaped spongy and main inflammation components [213]. Other drugs in molecule shape have been investigated, such as 5-fluorouracil and ibuprofen [214–216]. In addition to the molecular-shape drugs, rhBMP-2 is a protein based on recombinant human bone morphogenetics incorporated into scaffold-based PU and implanted for defects healing in the rat femoral bone. The results showed that the formation of bone increased after four weeks of implantation [217].

In another study, a PU that contained 5-aminosalicylic acid (5-ASA) was used, and results showed that the urethane group hydrolysis caused a release of drugs [218]. Also, Ghosh and Mandal reported on the release of ibuprofen based on PU structure [219]. It has been reported that drug incorporation does not considerably affect PU's biological and mechanical properties. Simmons *et al* reported that after using dexamethasone acetate in PU based on siloxane, there were no considerable differences in biocompatibility and biostability after six months of implantation in an animal model [220]. Drug delivery by PU-based carriers can be affected by some factors. For example, Da Silva *et al* investigated that the presence of poly(caprolactone) together with poly(ethylene glycol) as a soft segment in PU could enhance the release rate of dexamethasone acetate compared to PU with poly(caprolactone) alone. Furthermore, it was shown that the structure of PU was also involved in drug release behavior [221].

Furthermore, the use of ionic ligands has been shown to accelerate the release of drugs from PU-based carriers [222]. It has also been reported that the drugs' properties and functions can influence the drug release rate from the PU carrier [223]. This suggests that the drug itself plays an essential role in determining the release kinetics of the carrier. The factors related to the drugs' properties and functions, such as their molecular weight, hydrophobicity, and charge, can influence their interaction with the PU carrier, thereby affecting the drug release rate. For example, drugs with a higher molecular weight or greater hydrophobicity may have a slower release rate from the PU carrier, as they may be more strongly bound to the material.

Similarly, drugs with a higher charge may interact more strongly with ionic ligands, resulting in a faster release rate. Moreover, using ionic ligands can accelerate the release of drugs from a carrier base. E.g. Grigoreva reported that changing the PU structure (soft and hard segments) could make it possible to design composite PUs based on desired drug delivery. Another example; is the release of drugs, such as naltrexone, cefazolin, and piroxicam, on the base cross-linked PUs and dioxidine for linear PUs was shown to have an effect [224].

Gentile *et al* investigated a system based on ceramics scaffolds coated with gelatin. Then, they incorporated PU nanoparticles into the gelatin, loaded with indomethacin (IDMC), into the scaffold. Incorporated PU nanoparticles allowed a sustained IDMC release at about 65%–70% during the first week, and compressive modulus was increased [225]. Kolmas *et al* also used a system containing PU and HA to avoid cell invasion and the growth of bone tumours in the extracellular matrix (ECM). The system was designed to facilitate a prolonged release of bisphosphonates. The results showed that the release rate varied from 20% to 80%, indicating a possibility of controlling the release kinetics [226]. Guo *et al* worked on stent coatings based on biodegradable PU and were able to adjust the drug release [21, 227]. Polymer nanoparticles were analysed for improvement in cancer chemotherapy. Therefore, declining drug resistance and improving synergy in malignant lesions are necessary. Nanoparticles based on PU can co-encapsulate chemotherapeutic agents, such as doxorubicin and doxorubicin hydrochloride [228]. Tissue adhesives based on PU can also be applied as a delivery system to release antibiotics and painkillers [171] slowly. Some types of PU that have been investigated so far are summarised in table 4 [229].

Table 4. The different types of PU and model drugs for the delivery system [229].

Application	Drug used	Author	PU type	References
Gels	Crystal violet	Kohjiya <i>et al</i>	PU gels, were prepared from hydroxyl-terminated poly-(oxytetramethylene) and hydroxyl-terminated poly(oxyethylene)- <i>b</i> -poly(oxytetramethylene)- <i>b</i> -poly(oxyethylene)	[230]
Azo-containing PU as drug-coating	Model drugs-hydrophilic in nature-	Yamaoka <i>et al</i>	A segmented PU containing azo aromatic groups in the main chain was synthesized by reaction of isophorone diisocyanate with a mixture of <i>m,m'</i> -di(hydroxymethyl)azobenzene, poly(ethylene glycol) (Mn = 2000), and 1,2-propanediol	[231]
Ibuprofen bearing PU	Ibuprofen	Ghosh and Mandal	Polyethylene glycol (PEG) based PU bearing non-steroidal ibuprofen drug and release characteristics of ibuprofen from this polymeric backbone were investigated. Drug release was based on the degradation of ester linkages	[219]
Scaffolds	Platelet-derived growth factor (PDGF)	Li <i>et al</i>	—	[232]
Scaffolds	Recombinant human bone morphogenetic protein (rhBMP)	Li <i>et al</i>	Polyester triols (900 Da) were prepared from a glycerol starter and a backbone comprising 60 wt% ϵ -caprolactone, 30 wt% glycolide, and 10 wt% D,L-lactide In order to incorporate protein into PU scaffold, lyophilized protein powder, poly(lactic-co-glycolic acid)-large microspheres (PLGA-L), or small microspheres (PLGA-S) was added to the hardener component before mixing with the isocyanate to prepare the scaffolds	[217]
Pressure-sensitive adhesives (PSAs)	Thiamazole, diclofenac sodium, ibuprofen	Chen <i>et al</i>	PEG-based PU pressure-sensitive	[211]
Nano-structured polymers	Cefamandole nafate	Crisante <i>et al</i>	A polyetherurethane acid was obtained from the condensation of methylene bis-phenyl-isocyanate (MDI, Polyscience Inc.), polypropylene oxide (PPO, number average molecular weight 1200 Fluka) and dihydroxymethyl-propionic acid (DHMPA) in a 2:1:1 stoichiometric ratio	[233]
Foams	DB-67 and doxorubicin	Sivak <i>et al</i>	PU foams constructed from lysine diisocyanate (LDI) and glycerol	[234]
PU intravaginal rings	Dapivirine and tenofovir	Johnson <i>et al</i>	—	[235]
Films	Chlorhexidine diacetate (CDA)	Huynh <i>et al</i>	Medical grade PU (3M Unitek, Cergy Pontoise, France) was used as a polymer to incorporate CDA	[236]
PU matrix containing albumin nanoparticles	Cefamandole nafate	Martinelli <i>et al</i>	Carboxylated PU	[237]
Nanoparticles	Adriamycin	Sun <i>et al</i>	Temperature-sensitive polymers consisting of PEG and L-lysine ester diisocyanate	[238]

(Continued.)

Table 4. (Continued.)

Application	Drug used	Author	PU type	References
Film as a stent covering	Gemcitabine	Shin <i>et al</i>	<i>N,N</i> -dimethylacetamide (DMAc) and tetrahydrofuran (THF) Were reagent grade, and poly(carbonate urethane) ChronoFlex AL 85A was used	[239]
pH- and temperature responsive PU (nanoparticles)	Doxorubicin	Wang <i>et al</i>	A series of temperature- and pH-responsive PUs based on hexamethylene diisocyanate (HDI) and 4,4'-diphenylmethane diisocyanate (MDI) were synthesized	[240]
Tablets	Diprophylline	Claeys <i>et al</i>	Mixtures of diprophylline (Dyph) and TPU (ratio: 50/50, 65/35 and 75/25 wt.%) were used	[241]
Thermoplastic PU	Metoprolol tartrate	Vervae <i>et al</i>	TPU	[242]
Dual stimuli-responsive PU-based hydrogels	Ibuprofen	Laurano <i>et al</i>	A thermo- and pH-responsive hydrogel was prepared from a synthesized amphiphilic poly(ether urethane), exposing a considerable amount of -COOH groups (8.8 ± 0.9 nmol/g _{polymer}).	[243]

In conclusion, PUs family is widely used in biomedical applications. According to the adjustable physical and chemical properties of PUs, it is possible to change the degree of crystallinity and their interaction with water. Since PUs have appropriate biocompatibility, low cytotoxicity, and good mechanical properties, they have the potential to overcome challenges in drug delivery systems [218, 219]. By further attempting to have more *in vivo* investigation, more applications, limitations, and challenges of PUs for controlled drug delivery can be found.

4.2. PU applications in tissue engineering (TE)

PU has been investigated as a biomaterial for various tissue TE applications due to its unique properties, such as biocompatibility, flexibility, strength, and durability. Scaffolds are critical to TE as they support cells to grow and differentiate into functional tissue. The properties of PU, such as biocompatibility, flexibility, and durability, make it an attractive material for scaffolds [244]. PU-based scaffolds can mimic the mechanical properties of natural tissue and can be designed to provide a suitable environment for cell growth and differentiation [245]. PU-based scaffolds have been developed for various TE applications, including skin, cartilage, bone, and nerve tissue. For example, PU-based scaffolds have been developed to repair skin for treating burns and wounds. These scaffolds can support cells to grow and differentiate into functional skin tissue [246]. PU-based scaffolds can also be used to repair cartilage and bone tissue. These scaffolds can support cells to grow and differentiate into functional cartilage and bone tissue [247]. PU-based scaffolds have also been used in nerve TE, as they can mimic the mechanical properties of the nerve and provide a suitable environment for the growth and differentiation of neural cells [248]. PU scaffolds can have a variety of morphologies depending on the manufacturing process and the specific application [60]. The morphology of a PU scaffold refers to the physical structure and shape of the scaffold. PU can be fabricated as a porous structure (figure 10), to improve and enhance proliferation, cell adhesion, and differentiation.

Some typical morphologies of PU scaffolds include:

- (1) **Foam:** PU scaffolds can be made in foam, a porous, spongy material with a high surface area-to-volume ratio. Foam scaffolds are lightweight and easy to handle, and they can provide a suitable environment for cell growth and differentiation [247, 250].
- (2) **Fibrous:** PU scaffolds can also be processed in thin fibres and elongated structures that mimic natural tissue structures. Fibrous PU scaffolds can provide a suitable environment for cell growth and differentiation. They can be used in many TE applications, such as tubular structures for blood vessel regeneration, nerve guides for peripheral nerve regeneration, and cartilage TE constructs [248, 251].
- (3) **Film/coating:** PU scaffolds can also be made as a film. Film scaffolds can be used in many applications, such as wound dressings, cell culture substrates, or coating materials to modify the substrate's surface properties to provide an active environment for cell growth and differentiation or an additional layer of protection [141, 252–255].





Figure 11 shows a hybrid gelatin-based electrospun scaffold that the use of biodegradable polycarbonate PU has fabricated. It is supposed that adding PU could enable a tailored degradation rate and an increased mechanical strength compared to electrospun gelatin. Adding 20% PU to gelatin scaffolds (gelatin 80–polycarbonate PU 20) significantly increased the scaffolds' yield strength, degradation resistance, and elongation. Gelatin 100 had an elastic modulus of 130 ± 10 kPa, whereas the addition of 20% PU enhanced the elastic modulus to 260 ± 11 kPa. Gelatin 80–PU 20 showed the greatest elongation at break (60.7 ± 4.8), while this parameter was 34.7 ± 7.7 for gelatin 100. *In vivo* studies using a mouse excisional wound biopsy grafted with the scaffolds demonstrated that the gelatin 80–PU 20 scaffold enables more significant cell infiltration than clinically established matrices.

The findings show that electrospun gelatin 80–PU 20 scaffolds can generate tissue substitutes and overcome some limitations of conventional wound care matrices [256].

Topography can control the behaviour of cells, such as proliferation and growth alignment. Moreover, the shape change (stimulus-regulated swelling and shrinking) benefits the release of encapsulated agents in a precisely controllable manner [257, 258]. Additionally, the scaffold should benefit from a targeted degradation rate, and this rate should be designed based on the new tissue formation rate. Modifying PU with

ascorbic acid (vitamin C) can improve material properties for applications in soft tissue [259]. Shahrousvand *et al* also incorporated some iron oxide nanoparticles in PUs for TE applications [260]. Results indicated that the produced material had good potential in cell therapy applications. Li *et al* fabricated a scaffold containing hydroxyapatite (HA)/PU. Glyceride of castor oil (GCO) was applied to modify the soft part of PU. Finally, it was added to enhance the compressive strength, which increased when the HA particles were added.

Moreover, the HA particles were essential in bonding with the bone tissue and GCO-PU matrix interface [261]. HA and PU have been investigated more because HA can improve bioactivity, and PU can provide an excellent mechanical property [262]. Haryńska *et al* designed a 3D-printed filament based on PCL and PU for medical applications [14]. Also, thermoplastic-elastomer PU has been reviewed for its potential as a filament for FDM 3D printers [263]. Piotrowska-Kirschling conducted a study on the combination of chitosan and PU. It was reported that the presence of chitosan accelerates PU degradation. The combination of chitosan and PU was introduced as a highly biocompatible and bioactive combination that can be a good candidate in TE applications [264].

Additionally, the combination of chitosan and chitin with PU caused the creation of an applicable and influential composite for the biomedical field. The amino, carbamate, and acetamide groups (in chitosan, PU, and chitin, respectively) play a prominent role in making a material suitable for medical applications. In another investigation, collagen and PU were reviewed for TE application [265].

The use of PU for 3D-printed scaffolds is currently receiving much attention. The methods studied are fused filament fabrication (FFF), inkjet printing, stereolithography (SLA), and low-temperature deposition. Scaffolds based on poly(carbonate-urea) urethane enhance surface adherence and cell viability; therefore, they can become a polymer to improve laryngeal regeneration and reconstruction [266, 267]. In addition, elastomeric-PU can avoid shear forces between implant and bone, supporting osteogenic cells' proliferation in hard tissue. Regarding soft tissue, PU-based scaffolds can be applied to muscle regeneration, blood vessels, heart tissue, cartilage, and nerve [268].

A novel PU scaffold containing megni oil was used in TE due to its ability to enhance antithrombogenicity [269]. On the other hand, angiogenesis is another hot topic in the biomaterials field, and many researchers are trying to design a material that either inhibits or improves it. Colloidal aggregates and gels based on the mediated aggregation of cationic-PU particles have been applied to produce a matrix [270–272]. Notably, PU-based scaffolds have been established for the repair and regeneration of bone tissue based on osteogenic differentiation and proliferation [52, 273]. Membranes of PU and silk fibroin were designed and evaluated to mimic oral soft tissue [274]. The biological effect of these membranes was analysed regarding cell proliferation, cell adhesion, phosphatase activity, calcium content, and viability. These membranes seemed adequate for bone tissue regeneration [274, 275].

It is worth noting that the scaffold properties can be modified to suit the specific TE application by adjusting the polymer properties, such as porosity, mechanical properties, and degradation rate. Moreover, developing these scaffolds is still ongoing as the field of TE is rapidly advancing.

Though some major challenges persist, the future of PU scaffolds is promising. The PU scaffolds in a specific form targeted for a specific organ or tissue can be investigated. Thus, for future recommendations, a multidisciplinary approach is still required for fully exploiting PU scaffolds, combined with computational approaches for designing patient-specific PUs TE scaffolds. As a result, more investigations are required to narrow the differences between the cell interactions of PUs scaffolds in the *in vivo* and *in vivo* environments [276].

4.3. PUs for wound healing

The wound-healing process involves regenerating epidermal and dermal tissues that heal the wound. Successful wound healing involves interaction between dermal and epidermal cells, angiogenesis, and ECM. These can be regulated by growth factors and cytokines [277]. It has been reported that an ideal wound dressing should have specific characteristics and properties, such as a high level of bacterial resistance to removing exogenous microorganisms, sufficient haemostatic properties, high fluid adsorption, specific mechanical properties, stability, the ability to be removed easily, cost-effectiveness and recyclability [278]. In this regard, Unnithan *et al* investigated the fabrication of nanofibre composites for wound dressing based on cellulose, PU, and zein with streptomycin sulfate. The results showed perfect cell attachment, antibacterial activity, hydrophilicity, and blood clotting [137]. Also, mats based on nanofibrous composites containing gelatine, chitosan, and SMPU were fabricated by electrospinning and post-treated with silver nitrate (AgNO_3) solution. The obtained data illustrated that the produced composite could be a good candidate for wound dressing because it showed adequate antibacterial activity, an appropriate water vapour transmission rate, surface wettability, cytocompatibility, and haemostatic properties [279]. In another investigation, a combination of hydrogel and PU produced a composite for wound healing. The fabricated composite could accelerate wound healing and reduce the formation of scars [280]. PU compositions are selected for wound





Figure 12. Top panel. Schematic of synthesizing a scaffold containing PU, HA and EEP (modified). Lower Panel: Macroscopic photos of the wound healing process with three different specimens in 1, 7, 14, and 21 d (modified). Reprinted from [282], Copyright (2020), with permission from Elsevier.

healing applications based on their chemical composition, shape, and functionalization [7, 281]. Transparent and thin PU films are primarily suitable for surface protection and wounds after an operation with less or no exudate secretion. These PUs are not permeable to water and bacteria but are permeable to gases. As a result, they can help wounds to breathe.

PU foams are absorbent and suitable for wounds with more exudate [281]. Salehi *et al* designed a nanofibre matrix based on polyurethane and hyaluronic acid (PU-HA). This nanofibre matrix was enriched with various concentrations of ethanollic extract of propolis (EEP) (figure 12, top panel).

Results demonstrated that the PU-HA/1% EEP structure could be a good candidate for wound healing, with promising biocompatibility and antibacterial activity. It has been reported that PU in the composition accelerated the wound healing process (figure 12, lower panel) [282]. Also, lignin-based polyurethane foams loaded with Ag nanoparticles were investigated as a composite that showed good antibacterial activity in wound healing applications [283]. Even incorporating copper (Cu) in PU composites was reported to fabricate the nanofibrous composite for wound healing [284]. Another composition including PU for wound healing application has been introduced by Li *et al* [285]. A dressing material has been developed made of PU that possesses multiple functionalities. The designed material combines the electroactivity of aniline oligomer segments, the wettability of PEG segments, and the mechanical properties of PCL segments. The



films exhibited favourable hydrophilic properties and swelling ratio, exceptional mechanical strength and shape memory capabilities, electroactivity, effective free radical scavenging capacity, non-adherent properties, and biocompatibility.

PU has perfect properties for applications as pressure sensitive-adhesives (PSAs). These materials can provide appropriate adhesion to the base substrate, such as skin, with light pressure; as a result, they can be used in surgical dressing applications [286]. These materials' adhesion strength and breathability were improved by applying various crosslinkers [286]. Dressing foams based on PUs have good absorption of water and mechanical properties but less bioactivity and poor capability for healing. So, it has been suggested that incorporating and using bioactive nanoparticles like silica within the sol-gel process can improve the rate of wound closure and accelerate the regeneration of elastin fibre and collagen [287].

In summary, PUs as a wound dressing material have been commercially in the spotlight because of main characteristics such as biocompatibility, mechanical properties, elasticity, flexibility, and good oxygen/carbon dioxide permeability [288]. PUs can be a promising candidate for wound healing applications in the future. In addition, they expanded studies on the PUs to identify their limitations, challenges, advantages, and disadvantages for wound healing applications.

4.4. PUs for biosensors, and oral administration

PUs have been explored as a material for biosensors, devices that can detect and measure specific biomolecules such as glucose, proteins, and other biomolecules [289]. One of the key advantages of using PU in biosensors is its biocompatibility [290]. PU has good chemical stability and can withstand a wide range of pH and temperature conditions, making it a good biosensor choice [291, 292]. PU-based biosensors have been developed for various applications, including monitoring glucose levels in diabetes patients and detecting chemicals, toxins, and environmental pollutants. For example, PU-based glucose biosensors have been developed by immobilizing glucose oxidase enzymes onto a PU matrix, which can then be used to measure glucose levels in the blood [293].

Figure 13 shows a biosensor based on a nanofibre-based polydiacetylene (PDA) biosensor prepared with TPU to detect *E. coli*. 10,12-Pentacosadiynoic acid (PCDA) was used as a monomer for preparing PDA. In the electrospinning of PCDA and PU mixture solution, PCDA monomers were randomly distributed in the PU solution. PU-PDA nanofibre biosensors were prepared via electrospinning and tested with *E. coli*. The colour change in PU-PDA nanofibres began immediately when exposed to the *E. coli* concentration of approximately 9×10^8 CFU ml⁻¹. The nanofibre mat changed colour in some spots and immediately changed to red after a few minutes [294].

Another example is using PU-based biosensors for detecting environmental pollutants such as heavy metals, pesticides, and other toxins. These biosensors are typically based on immobilizing a specific enzyme or antibody onto a PU matrix, which can then detect the presence of a specific pollutant. A suitable biosensor should have some desired properties, including specificity, accuracy, stability, a wide range of analytical capabilities, low cost, and portability [295]. Many kinds of biosensors have been introduced to date [296], and many kinds of polymers (e.g. polyaniline, poly(vinylchloride), polypyrrole, and cellulose acetate) have been investigated as the substrate for the fabrication of biosensors [297, 298]. However, this application has widely used PU due to its appropriate biocompatibility, flexibility, cost-effectiveness, and easy processability [292, 299]. The key challenge in this route is the low solubility of hydrophobic drugs. Also, components of

drugs should keep their active state until they reach the absorption site [300, 301]. In order to achieve targeted drug absorption at a specific site, polymers can be coated onto the surface of drugs or mixed and linked with the drug to prevent potential degradation [231].

4.5. Drawbacks of PU in medical applications

While PU has many advantages and has been used in many medical applications, some drawbacks must be considered when using it in medical devices. Some of the drawbacks of the medical application of PU include [60, 163, 302, 303]:

Degradation over time: PU can degrade over time due to factors such as exposure to heat, chemicals, and microorganisms. This can lead to a loss of mechanical properties, such as strength and flexibility, and can affect the performance of the medical device [60, 163, 303, 304].

Allergic reactions: Some individuals may be allergic to PU, which can cause inflammation, itching, and other symptoms. This can be particularly problematic for long-term surgical implants [304, 305].

Incompatibility with imaging techniques: PU can interfere with specific imaging techniques, such as MRI, as it can cause image artefacts. This can make it challenging to diagnose and treat certain medical conditions accurately [306].

Sterilization issues: Sterilization problems are not unique to PU and can be challenging for many other polymers and materials used in medical devices, especially those with porous structures. Porous structures can harbour bacteria and other microorganisms, making them difficult to sterilize effectively. Furthermore, specific sterilization methods, such as gamma irradiation or ethylene oxide gas, can degrade or damage the polymer structure, reducing mechanical properties or potential toxicity. Therefore, careful consideration must be given to the choice of sterilization method and its potential effects on the polymer structure and device performance [79, 91, 307].

Cost: PU can be more expensive to manufacture than other medical device materials, such as polyethylene or polypropylene, due to the higher cost of raw materials and the more complex manufacturing processes involved.

PU requires specific chemical precursors, including isocyanates, polyols, and chain extenders, which can be more expensive than the raw materials used to produce other polymers. The production of PU also requires specialized equipment and more stringent manufacturing conditions, which can increase the overall cost of the process.

These drawbacks can vary depending on the specific type of PU used and the specific application. Therefore, it is essential to choose the appropriate PU type and consider the specific risks and benefits when using it in a medical application [302].

5. Conclusion and future perspective

- PU has already proven to be a versatile biomaterial with a wide range of applications in the medical field. Its unique properties, such as biocompatibility, flexibility, strength, and durability, make it an attractive option for many medical applications. Our findings from this review are as follows: PU family is rapidly advancing, and new developments are constantly being made. Therefore, it is expected that PU will continue to play an essential role in the medical field in the future. The future of polymer biomaterials is promising due to their advantages, including ease of processing. With its various properties, PU continues to have an essential role among polymers.
- The biostability of PU can potentially expand medical applications, including long- and short-term needs. Alternatively, controlled biodegradable PUs would eliminate the need for additional surgical procedures to remove the device. Examinations have shown that clinical applications can benefit from the long-term biostability achieved. While numerous approaches have been employed to enhance the resistance of polyurethane elastomers, compared to conventional PUs, against oxidative degradation, their suitability for extended medical implant usage remains to be assessed. Enhancing the comprehension of the interplay between PU chemical structure, properties, and biostability will enable synthetic polymer chemists to develop novel materials that cater to the demands of next-generation medical implants.
- Shape-memory PUs have the potential to be used in a wide range of medical applications, such as in biomedical devices, actuators, and robotics, where the ability to control the shape of the material is essential. The versatility and significance of shape memory SMPUs are evident in their diverse applications. External forces, including electricity, temperature, and light can trigger the shape memory effect in SMPUs. This response to external stimuli is due to the presence of both hard and soft segment domains in SMPUs. By employing cross-linking mechanisms such as ionic, covalent, and hydrogen bonding, it is possible to attain the desired properties in SMPUs.

- Using pH-responsive PUs has garnered attention in the pharmaceutical and biomedical fields. While there is significant potential in biomedical applications and drug delivery systems, further investigation is necessary to confirm their safety and efficacy in biological systems. It appears that in most studies focusing on pH-responsive PU systems for biomedical and drug delivery purposes, a detailed comparison of the stability, biodegradability, biocompatibility, and mechanical properties of PUs as potential polymeric substrates with other polymeric materials is lacking. Hence, more *in vivo* and *in vivo* studies on pH-responsive PUs must be conducted to ensure their safety *in vivo* and facilitate their future clinical use.
- While PUs face challenges when used in long-term blood-contacting devices, studies have shown that their mechanical properties and blood interaction can be improved through modifications in chemical composition and surface characteristics. This allows for the utilization of PUs in the development of cardiovascular devices, including heart valves and heart patches. These devices require materials with suitable properties such as strength and elastomeric behaviour to withstand cardiac contractile tissue and facilitate regeneration. Designing heart patches and valves that resemble muscle tissue structure is crucial. PUs are well-suited for cardiac applications due to their biocompatibility and ability to withstand cyclic heart stresses without deformation or fatigue failure. However, further efforts are required to bring PU-based cardiovascular devices into clinical use. Comprehensive and controlled *in vivo* and *in vivo* investigations are necessary for approval for PU-based cardiac patches and heart valves as medical devices.

Development of new PU-based hydrogels that absorb large amounts of water, making them ideal for wound dressings, drug delivery, and TE. PUs have gained attention as wound dressing materials due to their desirable properties, including biocompatibility, mechanical strength, elasticity, flexibility, and effective oxygen and carbon dioxide permeability. These characteristics make PUs a promising option for wound healing applications. But further research is needed to fully understand the limitations, challenges, advantages, and disadvantages of PUs in the context of wound healing.

Data availability statement

The data that support the findings of this study are available upon reasonable request from the authors.

Data access statement

Data access upon request to the corresponding author.

Acknowledgments

We acknowledge financial support from the Baltic Research Programme Project No. EEA-RESEARCH-85 'Waste-to-resource: eggshells as a source for next generation biomaterials for bone regeneration (EGGSHELL)' under the EEA Grant of Iceland, Liechtenstein and Norway No. EEZ/BPP/VIAA/2021/1Eggshell, Research Council of Norway, 'MISFAITH' Grant Nos. 331752 and Horizon 2020, 'BIOMATDB', Grant No. 101058779.

Conflict of interest

No conflict of interest reported.

ORCID iDs

Silvia Farè  <https://orcid.org/0000-0002-0303-1131>

Qianli Ma  <https://orcid.org/0000-0002-7044-8172>

Håvard J Haugen  <https://orcid.org/0000-0002-6690-7233>

References

- [1] Khatoon H and Ahmad S 2018 Polyurethane: a versatile scaffold for biomedical applications *Significances Bioeng. Biosci.* **2** 2–4
- [2] Joseph J, Patel R, Wenham A and Smith J 2018 Biomedical applications of polyurethane materials and coatings *Trans. IMF* **96** 121–9
- [3] Hulbert S F and Bowman L 1975 Porous polymeric orthopedic implants *Polymers in Medicine and Surgery* (Springer) pp 161–6
- [4] Wang W and Wang C 2012 Polyurethane for biomedical applications: a review of recent developments *The Design and Manufacture of Medical Devices* (Woodhead Publishing) pp 115–51
- [5] Pedersen D D, Kim S and Wagner W R 2022 Biodegradable polyurethane scaffolds in regenerative medicine: clinical translation review *J. Biomed. Mater. Res. A* **110** 1460–87

- [6] Akindoyo J O, Beg M, Ghazali S, Islam M, Jeyaratnam N and Yuvaraj A 2016 Polyurethane types, synthesis and applications—a review *RSC Adv.* **6** 114453–82
- [7] Pivec T, Smole M S, Gašparič P and Kleinschek K S 2017 Polyurethanes for medical use *Tekstilec* **60** 182–97
- [8] Burke A and Hasirci N 2004 Polyurethanes in biomedical applications *Biomaterials* pp 83–101
- [9] Christenson E, Anderson J and Hiltner A 2007 Biodegradation mechanisms of polyurethane elastomers *Corros. Eng. Sci. Technol.* **42** 312–23
- [10] Magnin A, Pollet E, Phalip V and Avérous L 2020 Evaluation of biological degradation of polyurethanes *Biotechnol. Adv.* **39** 107457
- [11] Park K-B, Kim H-T, Her N-Y and Lee J-M 2019 Variation of mechanical characteristics of polyurethane foam: effect of test method *J. Mater.* **12** 2672
- [12] Tan R Y, Lee C S, Pichika M R, Cheng S F and Lam K Y 2022 pH responsive polyurethane for the advancement of biomedical and drug delivery *Polymers* **14** 1672
- [13] Nakkabi A, Sadiki M, Fahim M, Ittobane N, IbsoudaKoraichi S, Barkai H and El Abed S 2015 Biodegradation of poly (ester urethane)s by *Bacillus subtilis* *Int. J. Environ. Res.* **9** 157–62
- [14] Haryńska A, Kucinska-Lipka J, Sulowska A, Gubanska I, Kostrzewa M and Janik H 2019 Medical-grade PCL based polyurethane system for FDM 3D printing—characterization and fabrication *J. Mater.* **12** 887
- [15] Hong S M et al 2022 Hyperelastic, shape-memorable and ultra-cell-adhesive degradable polycaprolactone-polyurethane copolymer for tissue regeneration *Bioeng. Transl. Med.* **7** e10332
- [16] Zafar K, Zia K M, Alzhhrani R M, Almalki A H and Alshehri S 2022 Biocompatibility and hemolytic activity studies of synthesized alginate-based polyurethanes *Polymers* **14** 2091
- [17] Hu J and Tan L 2017 *Polyurethane Composites and Nanocomposites for Biomedical Applications* (CRC Press)
- [18] Spiridon I, Anghel N, Dinu M V, Vlad S, Bele A, Ciubotaru B I, Verestiuc L and Pamfil D 2020 Development and performance of bioactive compounds-loaded cellulose/collagen/polyurethane biomaterials *Polymers* **12** 1191
- [19] Das A and Mahanwar P 2020 A brief discussion on advances in polyurethane applications *Adv. Ind. Eng. Polym. Res.* **3** 93–101
- [20] Ismail E A, Motawie A and Sadek E 2011 Synthesis and characterization of polyurethane coatings based on soybean oil–polyester polyols *Egypt. J. Pet.* **20** 1–8
- [21] Lowinger M B, Barrett S E, Zhang F and Williams III R O 2018 Sustained release drug delivery applications of polyurethanes *Pharmaceutics* **10** 55
- [22] Fernando S, McEnery M and Guelcher S A 2016 Polyurethanes for bone tissue engineering *Advances in Polyurethane Biomaterials* ed S L Cooper and J Guan (Woodhead Publishing) ch 16, pp 481–501
- [23] Alhanish A and Abu Ghalia M 2021 Biobased thermoplastic polyurethanes and their capability to biodegradation *Eco-Friendly Adhesives for Wood and Natural Fiber Composites* (Springer) pp 85–104
- [24] Shelke N B, Nagarale R K and Kumbar S G 2014 *Polyurethanes Natural and Synthetic Biomedical Polymers* (Elsevier)
- [25] Hung K-C, Tseng C-S and Hsu S-H 2016 3D printing of polyurethane biomaterials *Advances in Polyurethane Biomaterials* (Woodhead Publishing) pp 149–70
- [26] Parcheta P, Głowińska E and Datta J 2020 Effect of bio-based components on the chemical structure, thermal stability and mechanical properties of green thermoplastic polyurethane elastomers *Eur. Polym. J.* **123** 109422
- [27] Shi Y-D, Cheng Y-H, Chen Y-F, Zhang K, Zeng J-B and Wang M 2017 Morphology, rheological and crystallization behavior in thermoplastic polyurethane toughed poly (L-lactide) with stereocomplex crystallites *Polym. Test.* **62** 1–12
- [28] Polyurethanes Industry (API) 2002 Desmopan the link between rubber and engineering thermoplastics (American Plastics Council)
- [29] Mathur A B, Collier T O, Kao W J, Wiggins M, Schubert M A, Hiltner A and Anderson J M 1997 *In vivo* biocompatibility and biostability of modified polyurethanes *J. Biomed. Mater. Res.* **36** 246–57
- [30] Wang Y, Zou G and Shang L 2022 Effects of temperature and hard segment content on the interfacial mechanical properties of graphene/thermoplastic polyurethane composites: a molecular dynamics study *Comput. Mater. Sci.* **213** 111635
- [31] Ji X, Gao F, Geng Z and Li D 2021 Fabrication of thermoplastic polyurethane/poly lactide shape-memory blends with tunable optical and mechanical properties via a bilayer structure design *Polym. Test.* **97** 107135
- [32] Xu X, Fan P, Ren J, Cheng Y, Ren J, Zhao J and Song R 2018 Self-healing thermoplastic polyurethane (TPU)/polycaprolactone (PCL)/multi-wall carbon nanotubes (MWCNTs) blend as shape-memory composites *Compos. Sci. Technol.* **168** 255–62
- [33] Haugen H, Ried V, Brunner M, Will J and Wintermantel E 2004 Water as foaming agent for open cell polyurethane structures *J. Mater. Sci., Mater. Med.* **15** 343–6
- [34] Wen T-C, Y-I D and Digar M 2002 Compositional effect on the morphology and ionic conductivity of thermoplastic polyurethane based electrolytes *Eur. Polym. J.* **38** 1039–48
- [35] Prisacariu C and Scortanu E 2011 Influence of the type of chain extender and urethane group content on the mechanical properties of polyurethane elastomers with flexible hard segments *High Perform. Polym.* **23** 308–13
- [36] Lamba N, Woodhouse K and Cooper S 1998 *Polyurethanes in Biomedical Applications* (CRC Press)
- [37] Wu H et al 2022 The role of segmental mixing on the mechanical properties and oxidative stability of polydimethylsiloxane-based polyetherurethane *Polymer* **261** 125401
- [38] Li Y et al 2020 Enhanced hydrolytic resistance of fluorinated silicon-containing polyether urethanes *Biomacromolecules* **21** 1460–70
- [39] Badv M, Bayat F, Weitz J I and Didar T F 2020 Single and multi-functional coating strategies for enhancing the biocompatibility and tissue integration of blood-contacting medical implants *Biomaterials* **258** 120291
- [40] Bezuidenhout D, Williams D F and Zilla P 2015 Polymeric heart valves for surgical implantation, catheter-based technologies and heart assist devices *Biomaterials* **36** 6–25
- [41] Lelah M D and Cooper S L 1986 *Polyurethanes in Medicine* (CRC Press)
- [42] Grad S, Kupcsik L, Gorna K, Gogolewski S and Alini M 2003 The use of biodegradable polyurethane scaffolds for cartilage tissue engineering: potential and limitations *Biomaterials* **24** 5163–71
- [43] Beldi M, Medimagh R, Chatti S, Marque S, Prim D, Loupy A and Delolme F 2007 Characterization of cyclic and non-cyclic poly-(ether-urethane) s bio-based sugar diols by a combination of MALDI-TOF and NMR *Eur. Polym. J.* **43** 3415–33
- [44] Wołosz D, Parzuchowski P G and Świdarska A 2021 Synthesis and characterization of the non-isocyanate poly (carbonate-urethane)s obtained via polycondensation route *Eur. Polym. J.* **155** 110574
- [45] Shen Z, Zhang J, Zhu W, Zheng L, Li C, Xiao Y, Liu J, Wu S and Zhang B 2018 A solvent-free route to non-isocyanate poly (carbonate urethane) with high molecular weight and competitive mechanical properties *Eur. Polym. J.* **107** 258–66

- [46] Kiremitci M, Pulat M, Şenvar C, Şerbetçi A İ and Pişkin E 1990 Structural and cellular characterization of solvent-casted polyurethane membranes *Clin. Mater.* **6** 227–37
- [47] Elsner J J and McKeon B P 2017 Orthopedic application of polycarbonate urethanes: a review *Tech. Orthop.* **32** 132–40
- [48] Poljanšek I, Fabjan E, Moderc D and Kukanja D 2014 The effect of free isocyanate content on properties of one component urethane adhesive *Int. J. Adhes. Adhes.* **51** 87–94
- [49] Beyersdorf J 1992 Polyurethane prepolymers for immobilisation of living cells and enzymes. Development of immobilising procedures and characterisation of biocatalysts; Polyurethan-Praepolymere zur Immobilisierung von lebenden Zellen und Enzymen. Entwicklung von Immobilisierungsverfahren und Charakterisierung der Biokatalysatoren *PhD Thesis* Technische Univ. Braunschweig (available at: www.osti.gov/etdeweb/biblio/67433)
- [50] Li J, Chen Z and Yang X 2019 State of the art of small-diameter vessel-polyurethane substitutes *Macromol. Biosci.* **19** 1800482
- [51] Gu Y, Sun F, Xie X, Wu X, Zhang Z, Guidoin R, Fu Q, Zhong Y and Zhao C 2016 Prenatal developmental safety of functional polyurethanes for cardiovascular implants *J. Biomed. Mater. Res. B* **104** 606–14
- [52] Rusu L-C, Ardelean L C, Jitariu A-A, Miu C A and Streian C G 2020 An insight into the structural diversity and clinical applicability of polyurethanes in biomedicine *Polymers* **12** 1197
- [53] Ajili S H, Ebrahimi N and Soleimani M 2009 Polyurethane/polycaprolactane blend with shape memory effect as a proposed material for cardiovascular implants *Acta Biomater.* **5** 1519–30
- [54] Navas-Gómez K and Valero M F 2020 Why polyurethanes have been used in the manufacture and design of cardiovascular devices: a systematic review *Materials* **13** 3250
- [55] Vozzi F et al 2018 Biomimetic engineering of the cardiac tissue through processing, functionalization, and biological characterization of polyester urethanes *Biomed. Mater.* **13** 055006
- [56] Christenson E M, Dadsetan M, Wiggins M, Anderson J M and Hiltner A 2004 Poly (carbonate urethane) and poly (ether urethane) biodegradation: *in vivo* studies *J. Biomed. Mater. Res. A* **69** 407–16
- [57] Zhu R, Wang Y, Zhang Z, Ma D and Wang X 2016 Synthesis of polycarbonate urethane elastomers and effects of the chemical structures on their thermal, mechanical and biocompatibility properties *Heliyon* **2** e00125
- [58] Anderson J M, Rodriguez A and Chang D T 2008 Foreign body reaction to biomaterials *Semin. Immunol.* **20** 86–100
- [59] Rahmati M, Silva E A, Reseland J E, Heyward C A and Haugen H J 2020 Biological responses to physicochemical properties of biomaterial surface *Chem. Soc. Rev.* **49** 5178–224
- [60] Wendels S and Avérous L 2021 Biobased polyurethanes for biomedical applications *Bioact. Mater.* **6** 1083–106
- [61] Lyman D J, Kwan-Gett C, Zwart H H, Bland A, Eastwood N and Kawai J and Kolff W 1971 The development and implantation of a polyurethane hemispherical artificial heart *ASAIO J.* **17** 456–63
- [62] Ju M, Xu B and Xu L 2020 Synthesis and properties of blood compatible polyurethane elastomer *Chin. J. Org. Chem.* **40** 4344
- [63] Lehle K, Stock M, Schmid T, Schopka S, Straub R H and Schmid C 2009 *J. Biomed. Mater. Res. B* **90B** 312–8
- [64] Picha G and Gibbons D 1978 Effect of polyurethane morphology on blood coagulation *J. Bioeng.* **2** 301–11
- [65] Lyman D, Knutson K, McNeil B and Shibatani K 1975 The effects of chemical structure and surface properties of synthetic polymers on the coagulation of blood. IV. The relation between polymer morphology and protein adsorption *Trans. Am. Soc. Artif. Intern. Organs* **21** 49–54
- [66] Takahara A, Tashita J-I, Kajiyama T, Takayanagi M and MacKnight W J 1985 Microphase separated structure, surface composition and blood compatibility of segmented poly (urethaneureas) with various soft segment components *Polymer* **26** 987–96
- [67] Lelah M D, Pierce J A, Lambrecht L K and Cooper S L 1985 Polyether—urethane ionomers: surface property/*ex vivo* blood compatibility relationships *J. Colloid Interface Sci.* **104** 422–39
- [68] Cooper S L, Peppas N A, Hoffman A S and Ratner B D (eds) 1982 *Biomaterials: Interfacial Phenomena and Applications* (American Chemical Society)
- [69] Marois Y and Guidoin R 2013 Biocompatibility of Polyurethanes *Madame Curie Bioscience Database [Internet]* (Landes Bioscience)
- [70] Hsu S-H, Tseng H-J and Lin Y-C 2010 The biocompatibility and antibacterial properties of waterborne polyurethane-silver nanocomposites *Biomaterials* **31** 6796–808
- [71] Tseng H J, Lin J J, Ho T T, Tseng S M and Hsu S 2011 The biocompatibility and antimicrobial activity of nanocomposites from polyurethane and nano silicate platelets *J. Biomed. Mater. Res. A* **99** 192–202
- [72] Guo Y L, Wang W and Otaigbe J U 2010 Biocompatibility of synthetic poly (ester urethane)/polyhedral oligomeric silsesquioxane matrices with embryonic stem cell proliferation and differentiation *J. Tissue Eng. Regen. Med.* **4** 553–64
- [73] Melnig V, Apetroaei N, Dumitrascu N, Suzuki Y and Tura V 2005 Improvement of polyurethane surface biocompatibility by plasma and ion beam techniques *J. Optoelectron. Adv. Mater.* **7** 2521–8
- [74] Sobczak M 2015 Biodegradable polyurethane elastomers for biomedical applications—synthesis methods and properties *Polym. Plast. Technol. Eng.* **54** 155–72
- [75] Chien Y-C, Chuang W-T, Jeng U-S and Hsu S-H 2017 Preparation, characterization, and mechanism for biodegradable and biocompatible polyurethane shape memory elastomers *ACS Appl. Mater. Interfaces* **9** 5419–29
- [76] Mahajan N and Gupta P 2015 New insights into the microbial degradation of polyurethanes *RSC Adv.* **5** 41839–54
- [77] Barrioni B R, de Carvalho S M, Oréfice R L, de Oliveira A A R and de Magalhães Pereira M 2015 Synthesis and characterization of biodegradable polyurethane films based on HDI with hydrolyzable crosslinked bonds and a homogeneous structure for biomedical applications *Mater. Sci. Eng. C* **52** 22–30
- [78] Chase H, Mastoridis S and Maynard N 2021 AngelChik device removal and revisional fundoplication *J. Nuffield Dep. Surg. Sci.* **2** 1–6
- [79] Haugen H, Gerhardt L, Will J and Wintermantel E 2005 Biostability of polyether—urethane scaffolds: a comparison of two novel processing methods and the effect of higher gamma-irradiation dose *J. Biomed. Mater. Res. B* **73** 229–37
- [80] Gamerith C et al 2016 Improving enzymatic polyurethane hydrolysis by tuning enzyme sorption *Polym. Degrad. Stab.* **132** 69–77
- [81] Coste G, Berne D, Ladmiral V, Negrell C and Caillol S 2022 Non-isocyanate polyurethane foams based on six-membered cyclic carbonates *Eur. Polym. J.* **176** 111392
- [82] Zhang H, Cui X, Wang H, Wang Y, Zhao Y, Ma H, Chai L, Wang Y, Hou X and Deng T 2020 Degradation of polycarbonate-based polyurethane via selective cleavage of carbamate and urea bonds *Polym. Degrad. Stab.* **181** 109342
- [83] Wintermantel E and Ha S W 1998 *Biokompatible Werkstoffe* (Springer)
- [84] Lamba N M, Woodhouse K A and Cooper S L 2017 *Polyurethanes in Biomedical Applications* (Routledge)
- [85] Lyu S, Schley J, Loy B, Luo L, Hobot C, Sparer R, Untereker D and Krzeszak J 2008 *in vivo* biostability evaluation of polyurethane composites in acidic, basic, oxidative, and neutral solutions *J. Biomed. Mater. Res. B* **85** 509–18

- [86] Gunatillake P A, Martin D J, Meijs G F, McCarthy S J and Adhikari R 2003 Designing biostable polyurethane elastomers for biomedical implants *Aust. J. Chem.* **56** 545–57
- [87] Kang J, Erdodi G, Brendel C M, Ely D and Kennedy J P 2010 Polyisobutylene-based polyurethanes. V. Oxidative-hydrolytic stability and biocompatibility *J. Polym. Sci. A* **48** 2194–203
- [88] Cozzens D, Ojha U, Kulkarni P, Faust R and Desai S 2010 Long term *in vivo* biostability of segmented polyisobutylene-based thermoplastic polyurethanes *J. Biomed. Mater. Res. A* **95** 774–82
- [89] Ward R, Anderson J, McVenes R and Stokes K 2006 *in vivo* biostability of polysiloxane polyether polyurethanes: resistance to biologic oxidation and stress cracking *J. Biomed. Mater. Res. A* **77** 580–9
- [90] Wiggins M J, MacEwan M, Anderson J M and Hiltner A 2004 Effect of soft-segment chemistry on polyurethane biostability during *in vivo* fatigue loading *J. Biomed. Mater. Res. A* **68** 668–83
- [91] Haugen H J, Brunner M, Pellkofer F, Aigner J, Will J and Wintermantel E 2007 Effect of different γ -irradiation doses on cytotoxicity and material properties of porous polyether-urethane polymer *J. Biomed. Mater. Res. B* **80** 415–23
- [92] Ward R, Anderson J, McVenes R and Stokes K 2007 *In vivo* biostability of polyether polyurethanes with fluoropolymer and polyethylene oxide surface modifying endgroups; resistance to metal ion oxidation *J. Biomed. Mater. Res. A* **80** 34–44
- [93] Stachelek S J, Alferiev I, Ueda M, Eckels E C, Gleason K T and Levy R J 2010 Prevention of polyurethane oxidative degradation with phenolic antioxidants covalently attached to the hard segments: structure–function relationships *J. Biomed. Mater. Res. A* **94** 751–9
- [94] Hsu S-H and Chou C-W 2004 Enhanced biostability of polyurethane containing gold nanoparticles *Polym. Degrad. Stab.* **85** 675–80
- [95] Chou C-W, Hsu S-H, Chang H, Tseng S-M and Lin H-R 2006 Enhanced thermal and mechanical properties and biostability of polyurethane containing silver nanoparticles *Polym. Degrad. Stab.* **91** 1017–24
- [96] Yakai F, Li Z and Zhenzhen W 2007 Biodegradable polyurethanes in medical applications *Res. J. Chem. Environ.* **11** 78–83
- [97] Guelcher S A 2008 Biodegradable polyurethanes: synthesis and applications in regenerative medicine *Tissue Eng. B* **14** 3–17
- [98] Cregut M, Bedas M, Durand M J and Thouand G 2013 New insights into polyurethane biodegradation and realistic prospects for the development of a sustainable waste recycling process *Biotechnol. Adv.* **31** 1634–47
- [99] Bakker D, Van Blitterswijk C, Hesselings S, Daems W T and Grote J 1990 Tissue/biomaterial interface characteristics of four elastomers. A transmission electron microscopical study *J. Biomed. Mater. Res.* **24** 277–93
- [100] Gantz D, Bertoldi S, Contessi Negrini N and Haugen H J 2019 Polymers and scaffolds with improved blood compatibility and enhanced cellular response with focus on polyurethane foams functionalized with amino-amide groups *J. Adv. Biotechnol. Bioeng.* **7** 18–29
- [101] Mohanty M, Hunt J, Doherty P, Annis D and Williams D 1992 Evaluation of soft tissue response to a poly [urethane urea] *Biomaterials* **13** 651–6
- [102] Wilkins E 1991 Tissue reaction to intraperitoneally implanted catheter materials *J. Biomed. Eng.* **13** 173–5
- [103] Haugen H J, Wintermantel E, Leicher S and Will J 2005b Microcellular injection molding as large scale processing method for non-toxic porous cell carriers made of polyurethane *European Congress on Advanced Materials and Processes (Prague)*
- [104] Wu H-B, Haugen H J and Wintermantel E 2012 Supercritical CO₂ in injection molding can produce open porous polyurethane scaffolds—a parameter study *J. Cell. Plast.* **48** 141–59
- [105] Haugen H J, Schneider A, Schlicht H, Wu H, Doundoulakis E, Wilhelm D and Feussner H 2022 Long-term *in vivo* response of a polyurethane gastric implant for treating gastro-oesophageal reflux diseases: a comparison of different surface treatments *Biomed. Mater. Dev.* **1**–20
- [106] Gunatillake P A, Dandeniya L S, Adhikari R, Bown M, Shanks R and Adhikari B 2019 Advancements in the development of biostable polyurethanes *Polym. Rev.* **59** 391–417
- [107] Santerre J, Woodhouse K, Laroche G and Labow R 2005 Understanding the biodegradation of polyurethanes: from classical implants to tissue engineering materials *Biomaterials* **26** 7457–70
- [108] Chandy T, Van Hee J, Nettekoven W and Johnson J 2009 Long-term *in vivo* stability assessment of polycarbonate urethane micro catheters: resistance to oxidation and stress cracking *J. Biomed. Mater. Res. B* **89** 314–24
- [109] Andriani Y, Morrow I C, Taran E, Edwards G A, Schiller T L, Osman A F and Martin D J 2013 *in vivo* biostability of poly (dimethyl siloxane/hexamethylene oxide)-based polyurethane/layered silicate nanocomposites *Acta Biomater.* **9** 8308–17
- [110] Styan K E, Martin D J, Simmons A and Poole-Warren L A 2012 *in vivo* biostability of polyurethane–organosilicate nanocomposites *Acta Biomater.* **8** 2243–53
- [111] Ramezani M and Monroe M B 2022 Biostable segmented thermoplastic polyurethane shape memory polymers for smart biomedical applications *ACS Appl. Polym. Mater.* **4** 1956–65
- [112] Deng Z, Guo Y, Zhao X, Li L, Dong R, Guo B and Ma P X 2016 Stretchable degradable and electroactive shape memory copolymers with tunable recovery temperature enhance myogenic differentiation *Acta Biomater.* **46** 234–44
- [113] Wu Y, Wang L, Zhao X, Hou S, Guo B and Ma P X 2016 Self-healing supramolecular bioelastomers with shape memory property as a multifunctional platform for biomedical applications via modular assembly *Biomaterials* **104** 18–31
- [114] Baek S H and Kim J H 2021 Shape memory characteristics of thermadappt polyurethane incorporated with two structurally distinctive aliphatic isocyanates *Polym. Test.* **103** 107366
- [115] Nissenbaum A, Greenfeld I and Wagner H D 2020 Shape memory polyurethane—amorphous molecular mechanism during fixation and recovery *Polymer* **190** 122226
- [116] Thakur S and Hu J 2017 *Polyurethane: A Shape Memory Polymer (SMP): Aspects of Polyurethanes* (Intechopen) pp 53–71
- [117] Sokolowski W, Metcalfe A, Hayashi S and Raymond J 2007 Medical applications of shape memory polymers *J. Biomed. Mater.* **2** S23
- [118] De Nardo L, Bertoldi S, Cigada A, Tanzi M C, Haugen H J and Farè S 2012 Preparation and characterization of shape memory polymer scaffolds via solvent casting/particulate leaching *J. Appl. Biomater. Funct. Mater.* **10** 119–26
- [119] Li Y, Chen H, Liu D, Wang W, Liu Y and Zhou S 2015 pH-responsive shape memory poly (ethylene glycol)–poly (ϵ -caprolactone)-based polyurethane/cellulose nanocrystals nanocomposite *ACS Appl. Mater. Interfaces* **7** 12988–99
- [120] Iqbal D and Samiullah M H 2013 Photo-responsive shape-memory and shape-changing liquid-crystal polymer networks *Materials* **6** 116–42
- [121] Mondal S 2009 Recent developments in temperature responsive shape memory polymers *Mini-Rev. Org. Chem.* **6** 114–9
- [122] Hager M D, Bode S, Weber C and Schubert U S 2015 Shape memory polymers: past, present and future developments *Prog. Polym. Sci.* **49** 3–33

- [123] Singhal P, Small W, Cosgriff-Hernandez E, Maitland D J and Wilson T S 2014 Low density biodegradable shape memory polyurethane foams for embolic biomedical applications *Acta Biomater.* **10** 67–76
- [124] Serrano M C and Ameer G A 2012 Recent insights into the biomedical applications of shape-memory polymers *Macromol. Biosci.* **12** 1156–71
- [125] Gupta A, Maharjan A and Kim B S 2019 Shape memory polyurethane and its composites for various applications *Appl. Sci.* **9** 4694
- [126] Zhao X, Dong R, Guo B and Ma P X 2017 Dopamine-incorporated dual bioactive electroactive shape memory polyurethane elastomers with physiological shape recovery temperature, high stretchability, and enhanced C2C12 myogenic differentiation *ACS Appl. Mater. Interfaces* **9** 29595–611
- [127] Chen H, Li Y, Liu Y, Gong T, Wang L and Zhou S 2014 Highly pH-sensitive polyurethane exhibiting shape memory and drug release *Polym. Chem.* **5** 5168–74
- [128] Ahmed N, Kausar A and Muhammad B 2015 Advances in shape memory polyurethanes and composites: a review *Polym. Plast. Technol. Eng.* **54** 1410–23
- [129] Nugroho W T, Dong Y, Pramanik A, Leng J and Ramakrishna S 2021 Smart polyurethane composites for 3D or 4D printing: general-purpose use, sustainability and shape memory effect *Composites B* **223** 109104
- [130] Wang X, He Y, Liu Y and Leng J 2022 Advances in shape memory polymers: remote actuation, multi-stimuli control, 4D printing and prospective applications *Mater. Sci. Eng. R* **151** 100702
- [131] Wei W, Liu J, Huang J, Cao F, Qian K, Yao Y and Li W 2022 Recent advances and perspectives of shape memory polymer fibers *Eur. Polym. J.* **175** 111385
- [132] Fu Y Q, Huang W M, Luo J K and Lu H 2015 Polyurethane shape-memory polymers for biomedical applications *Shape Memory Polymers For Biomedical Applications* (Woodhead Publishing) pp 167–95
- [133] De Nardo L, Bertoldi S, Tanzi M C, Haugen H and Fare S 2011 Shape memory polymer cellular solid design for medical applications *Smart Mater. Struct.* **20** 035004
- [134] Lewis C L and Dell E M 2016 A review of shape memory polymers bearing reversible binding groups *J. Polym. Sci. B* **54** 1340–64
- [135] Park S, Moon J, Kim B and Cho M 2021 Multi-scale coarse-grained molecular dynamics simulation to investigate the thermo-mechanical behavior of shape-memory polyurethane copolymers *Polymer* **213** 123228
- [136] Wang C H, Hou G G, Du Z Z, Cong W, Sun J F, Xu Y Y and Liu W-S 2016 Synthesis, characterization and antibacterial properties of polyurethane material functionalized with quaternary ammonium salt *Polym. J.* **48** 259–65
- [137] Unnithan A R, Gnanasekaran G, Sathishkumar Y, Lee Y S and Kim C S 2014 Electrospun antibacterial polyurethane-cellulose acetate-zein composite mats for wound dressing *Carbohydrate Polym.* **102** 884–92
- [138] Francolini I, Donelli G, Crisante F, Taresco V and Piozzi A 2015 Antimicrobial polymers for anti-biofilm medical devices *State-of-art and Perspectives, Biofilm-Based Healthcare-Associated Infections* (Springer) pp 93–117
- [139] Calamak S, Shahbazi R, Eroglu I, Gultekinoglu M and Ulubayram K 2017 An overview of nanofiber-based antibacterial drug design *Expert Opin. Drug Discov.* **12** 391–406
- [140] Kasi G, Gnanasekar S, Zhang K, Kang E T and Xu L Q 2022 Polyurethane-based composites with promising antibacterial properties *J. Appl. Polym. Sci.* **139** 52181
- [141] Wang C, Yi Z, Sheng Y, Tian L, Qin L, Ngai T and Lin W 2019 Development of a novel biodegradable and anti-bacterial polyurethane coating for biomedical magnesium rods *Mater. Sci. Eng. C* **99** 344–56
- [142] Jiang J, Fu Y, Zhang Q, Zhan X and Chen F 2017 Novel amphiphilic poly (dimethylsiloxane) based polyurethane networks tethered with carboxybetaine and their combined antibacterial and anti-adhesive property *Appl. Surf. Sci.* **412** 1–9
- [143] Javaid M A, Khera R A, Zia K M, Saito K, Bhatti I A and Asghar M 2018 Synthesis and characterization of chitosan modified polyurethane bio-nanocomposites with biomedical potential *Int. J. Biol. Macromol.* **115** 375–84
- [144] Ahmad Z, Vargas-Reus M, Bakhshi R, Ryan F, Ren G, Oktar F and Allaker R P 2012 Antimicrobial properties of electrically formed elastomeric polyurethane–copper oxide nanocomposites for medical and dental applications *Meth. Enzymol.* **509** 87–99
- [145] Rahman M M 2020 Polyurethane/zinc oxide (PU/ZnO) composite—synthesis, protective property and application *Polymers* **12** 1535
- [146] Farrokhi Z, Ayati A, Kanvisi M and Sillanpää M 2019 Recent advance in antibacterial activity of nanoparticles contained polyurethane *J. Appl. Polym. Sci.* **136** 46997
- [147] Wang C, Mu C, Lin W and Xiao H 2020 Functional-modified polyurethanes for rendering surfaces antimicrobial: an overview *Adv. Colloid Interface Sci.* **283** 102235
- [148] Shoab M, Bahadur A, Saeed A, Rahman M S U and Naseer M M 2018 Biocompatible, pH-responsive, and biodegradable polyurethanes as smart anti-cancer drug delivery carriers *React. Funct. Polym.* **127** 153–60
- [149] Kim S, Traore Y L, Chen Y, Ho E A and Liu S 2018 Switchable on-demand release of a nanocarrier from a segmented reservoir type intravaginal ring filled with a pH-responsive supramolecular polyurethane hydrogel *ACS Appl. Bio Mater.* **1** 652–62
- [150] Pardini F M and Amalvy J I 2014 Synthesis and swelling behavior of pH-responsive polyurethane/poly [2-(diethylamino) ethyl methacrylate] hybrid materials *J. Appl. Polym. Sci.* **131**
- [151] García-Fernández L, Mora-Boza A and Reyes-Ortega F 2019 pH-responsive polymers: properties, synthesis, and applications *Smart Polymers and Their Applications* (Elsevier)
- [152] Hua D et al 2016 pH responsive polyurethane (core) and cellulose acetate phthalate (shell) electrospun fibers for intravaginal drug delivery *Carbohydrate Polym.* **151** 1240–4
- [153] Santra S, Sk M A, Mondal A and Molla M R 2020 Self-immolative polyurethane-based nanoassemblies: surface charge modulation at tumor-relevant pH and redox-responsive guest release *Langmuir* **36** 8282–9
- [154] Cheng X, Jin Y, Qi R, Fan W, Li H, Sun X and Lai S 2016 Dual pH and oxidation-responsive nanogels crosslinked by diselenide bonds for controlled drug delivery *Polymer* **101** 370–8
- [155] Song Y, Chai Y, Xu K and Zhang P 2018 Functional polyurethane nanomicelle with pH-responsive drug delivery property *e-Polymers* **18** 409–17
- [156] Yu S, He C, Lv Q, Sun H and Chen X 2014 pH and reduction dual responsive cross-linked polyurethane micelles as an intracellular drug delivery system *RSC Adv.* **4** 63070–8
- [157] Morral-Ruiz G, Melgar-Lesmes P, Solans C and García-Celma M J 2016 Polyurethane nanoparticles, a new tool for biomedical applications? *Advances in Polyurethane Biomaterials* (Woodhead Publishing) pp 195–216
- [158] Kim S, Chen Y, Ho E A and Liu S 2017 Reversibly pH-responsive polyurethane membranes for on-demand intravaginal drug delivery *Acta Biomater.* **47** 100–12

- [159] Zhu Y J and Chen F 2015 pH-responsive drug-delivery systems *Chem. Asian J.* **10** 284–305
- [160] Douglas T and Haugen H J 2008 Coating of polyurethane scaffolds with collagen: comparison of coating and cross-linking techniques *J. Mater. Sci., Mater. Med.* **19** 2713–9
- [161] Khan W, Muntimadugu E, Jaffe M and Domb A J 2014 Implantable medical devices *Focal Controlled Drug Delivery* (Springer) pp 33–59
- [162] Claiborne T E, Slepian M J, Hossainy S and Bluestein D 2012 Polymeric trileaflet prosthetic heart valves: evolution and path to clinical reality *Expert Rev. Med. Devices* **9** 577–94
- [163] Crago M, Lee A, Farajikhah S, Oveissi F, Fletcher D F, Dehghani F and Naficy S 2022 The evolution of polyurethane heart valve replacements: how chemistry translates to the clinic *Mater. Today Commun.* **33** 10916
- [164] Wu W I, Sask K N, Brash J L and Selvaganapathy P R 2012 Polyurethane-based microfluidic devices for blood contacting applications *Lab Chip* **12** 960–70
- [165] Pant H R, Pokharel P, Joshi M K, Adhikari S, Kim H J, Park C H and Kim C S 2015 Processing and characterization of electrospun graphene oxide/polyurethane composite nanofibers for stent coating *Chem. Eng. J.* **270** 336–42
- [166] Gultekinoglu M, Sarisozen Y T, Erdogdu C, Sagiroglu M, Aksoy E A, Oh Y J, Hinterdorfer P and Ulubayram K 2015 Designing of dynamic polyethyleneimine (PEI) brushes on polyurethane (PU) ureteral stents to prevent infections *Acta Biomater.* **21** 44–54
- [167] Black J, Alves P, Brindle C T, Dealey C, Santamaria N, Call E and Clark M 2015 Use of wound dressings to enhance prevention of pressure ulcers caused by medical devices *Int. Wound J.* **12** 322–7
- [168] Li H, Sinha T K, Oh J S and Kim J K 2018 Soft and flexible bilayer thermoplastic polyurethane foam for development of bioinspired artificial skin *ACS Appl. Mater. Interfaces* **10** 14008–16
- [169] Members W G et al 2012 Heart disease and stroke statistics—2012 update: a report from the American Heart Association *Circulation* **125** e2–220
- [170] Ounpuu S, Anand S and Yusuf S 2000 The impending global epidemic of cardiovascular diseases *Eur. Heart J.* **21** 880–3
- [171] Teebken O E and Haverich A 2002 Tissue engineering of small diameter vascular grafts *Eur. J. Vasc. Endovasc. Surg.* **23** 475–85
- [172] Kütting M, Roggenkamp J, Urban U, Schmitz-Rode T and Steinseifer U 2011 Polyurethane heart valves: past, present and future *Expert Rev. Med. Devices* **8** 227–33
- [173] Pawlowski K J, Rittgers S E, Schmidt S P and Bowlin G L 2004 Endothelial cell seeding of polymeric vascular grafts *Front. Biosci.* **9** 1412–21
- [174] Lee S J, Liu J, Oh S H, Soker S, Atala A and Yoo J J 2008 Development of a composite vascular scaffolding system that withstands physiological vascular conditions *Biomaterials* **29** 2891–8
- [175] Arjun G and Ramesh P 2012 Structural characterization, mechanical properties, and *in vivo* cytocompatibility evaluation of fibrous polycarbonate urethane membranes for biomedical applications *J. Biomed. Mater. Res. A* **100** 3042–50
- [176] Kuan Y H, Dasi L P, Yoganathan A and Leo H L 2011 Recent advances in polymeric heart valves research *Int. J. Biomater. Res. Eng.* **1** 1–19
- [177] Vermette P, Griesser H J, Laroche G and Guidoin R 2001 *Biomedical Applications of Polyurethanes* (Landes Bioscience)
- [178] Hu T, Wu Y, Zhao X, Wang L, Bi L, Ma P X and Guo B 2019 Micropatterned, electroactive, and biodegradable poly (glycerol sebacate)-aniline trimer elastomer for cardiac tissue engineering *J. Chem. Eng.* **366** 208–22
- [179] Sarkar S, Burriesci G, Wojcik A, Aresti N, Hamilton G and Seifalian A M 2009 Manufacture of small calibre quadruple lamina vascular bypass grafts using a novel automated extrusion-phase-inversion method and nanocomposite polymer *J. Biomech.* **4** 722–30
- [180] Solis-Correa R E, Vargas-Coronado R, Aguilar-Vega M, Cauich-Rodriguez J, Román J S and Marcos A 2007 Synthesis of HMDI-based segmented polyurethanes and their use in the manufacture of elastomeric composites for cardiovascular applications *Biomater. Sci. Polym. Ed.* **18** 561–78
- [181] Boretos J W and Pierce W S 1968 Segmented polyurethane: a polyether polymer. An initial evaluation for biomedical applications *J. Biomed. Mater. Res.* **2** 121–30
- [182] Mi H Y, Jing X, Li Z T, Lin Y J, Thomson J A and Turng L S 2019 Fabrication and modification of wavy multicomponent vascular grafts with biomimetic mechanical properties, antithrombogenicity, and enhanced endothelial cell affinity *J. Biomed. Mater. Res. B* **107** 2397–408
- [183] H-y M, Jiang Y, Jing X, Enriquez E, Li H, Li Q and Turng L-S 2019 Fabrication of triple-layered vascular grafts composed of silk fibers, polyacrylamide hydrogel, and polyurethane nanofibers with biomimetic mechanical properties *Mater. Sci. Eng. C* **98** 241–9
- [184] Çelebi-Saltik B, Öteyaka M Ö and Gökçinar-Yağci B 2021 Stem cell-based small-diameter vascular grafts in dynamic culture *Connect. Tissue Res.* **62** 151–63
- [185] Gossart A, Letourneur D, Gand A, Regnault V, Mlouka M A B, Cosette P, Pauthe E, Ollivier V and Santerre J P 2019 Mitigation of monocyte driven thrombosis on cobalt chrome surfaces in contact with whole blood by thin film polar/hydrophobic/ionic polyurethane coatings *Biomaterials* **217** 119306
- [186] Hasan J, Crawford R J and Ivanova E P 2013 Antibacterial surfaces: the quest for a new generation of biomaterials *Trends Biotechnol.* **31** 295–304
- [187] Villani M, Consonni R, Canetti M, Bertoglio F, Iervese S, Bruni G, Visai L, Iannace S and Bertini F 2020 Polyurethane-based composites: effects of antibacterial fillers on the physical-mechanical behavior of thermoplastic polyurethanes *Polymers* **12** 362
- [188] Oveissi F, Naficy S, Lee A, Winlaw D and Dehghani F 2020 Materials and manufacturing perspectives in engineering heart valves: a review *Mater. Today Bio* **5** 100038
- [189] Rau J V, Cacciotti I, Laureti S, Fosca M, Varvaro G and Latini A 2015 Bioactive, nanostructured S i-substituted hydroxyapatite coatings on titanium prepared by pulsed laser deposition *J. Biomed. Mater. Res. B* **103** 1621–31
- [190] Cooper S L and Guan J 2016 *Advances In Polyurethane Biomaterials* (Woodhead Publishing)
- [191] Joshi R R, Frautschi J R, Phillips Jr R E and Levy R J 1994 Phosphonated polyurethanes that resist calcification *J. Biomater. Appl.* **5** 65–77
- [192] Pierce W S, Donachy J H, Rosenberg G and Baier R E 1980 Calcification inside artificial hearts: inhibition by warfarin-sodium *Science* **208** 601–3
- [193] Dostal M, Vaškú J, Vaškú J, Šotolová O, Vaškú A, Doležel S and Hartmannová B 1990 Mineralization of polyurethane membranes in the total artificial heart (TAH): a retrospective study from long-term animal experiments *Artif. Organs* **13** 498–502
- [194] Wilson A C, Chou S-F, Lozano R, Chen J Y and Neuenschwander P F 2019 Thermal and physico-mechanical characterizations of thromboresistant polyurethane films *Bioengineering* **6** 69

- [195] Szott L M and Horbett T A 2011 Protein interactions with surfaces: cellular responses, complement activation, and newer methods *Curr. Opin. Chem. Biol.* **15** 677–82
- [196] Parrag I C, Zandstra P W and Woodhouse K A 2012 Fiber alignment and coculture with fibroblasts improves the differentiated phenotype of murine embryonic stem cell-derived cardiomyocytes for cardiac tissue engineering *Biotechnol. Bioeng.* **109** 813–22
- [197] De Gaetano F, Serrani M, Bagnoli P, Brubert J, Stasiak J, Moggridge G D and Costantino M L 2015 Fluid dynamic characterization of a polymeric heart valve prototype (Poli-Valve) tested under continuous and pulsatile flow conditions *Artif. Organs* **38** 600–6
- [198] Shi M, Bai L, Xu M, Li Z, Hu T, Hu J, Zhang Z, Yin Z and Guo B 2022 Micropatterned conductive elastomer patch based on poly (glycerol sebacate)-graphene for cardiac tissue repair *Biofabrication* **14** 035001
- [199] Smith T B 2010 MRI artifacts and correction strategies *Imaging Med.* **2** 445
- [200] Jenney C, Millson P, Grainger D W, Grubbs R, Gunatillake P, McCarthy S J and Beith J 2021 Assessment of a siloxane poly(urethane-urea) elastomer designed for implantable heart valve leaflets *Adv. Biomed. Res.* **1** 2000032
- [201] Alves P, Ferreira P and Gil M 2012 Biomedical polyurethanes-based materials *Polyurethane: Properties, Structure and Applications, Polymer Science and Technology* (Nova Publishers) pp 25–50
- [202] Boffito M, Sartori S, Mattu C and Ciardelli G 2016 Polyurethanes for cardiac applications *Advances In Polyurethane Biomaterials* (Woodhead Publishing) pp 387–416
- [203] Zhou L, Liang D, He X, Li J, Tan H, Li J, Fu Q and Gu Q 2012 The degradation and biocompatibility of pH-sensitive biodegradable polyurethanes for intracellular multifunctional antitumor drug delivery *Biomaterials* **33** 2734–45
- [204] Cherg J Y, Hou T Y, Shih M F, Talsma H and Hennink W E 2013 Polyurethane-based drug delivery systems *Int. J. Pharm.* **450** 145–62
- [205] Freiberg S and Zhu X 2004 Polymer microspheres for controlled drug release *Int. J. Pharm.* **282** 1–18
- [206] Acharya G and Park K 2006 Mechanisms of controlled drug release from drug-eluting stents *Adv. Drug Deliv. Rev.* **58** 387–401
- [207] Marzec M, Kucińska-Lipka J, Kalaszczyńska I and Janik H 2017 Development of polyurethanes for bone repair *Mater. Sci. Eng. C* **80** 736–47
- [208] Kaviannasab E, Semnani D, Khorasani S N, Varshosaz J, Khalili S and Ghahreman F 2019 Core-shell nanofibers of poly (ϵ -caprolactone) and polyvinylpyrrolidone for drug delivery system *Mater. Res. Express* **6** 115015
- [209] Cacciotti I et al 2018 Controlled release of 18- β -glycyrrhetic acid by nanodelivery systems increases cytotoxicity on oral carcinoma cell line *Nanotechnology* **29** 285101
- [210] Coimbra P A, Sousa H C D and Gil M H 2008 Preparation and characterization of flurbiprofen-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) microspheres *J. Microencapsul.* **25** 170–8
- [211] Chen X, Liu W, Zhao Y, Jiang L, Xu H and Yang X 2009 Preparation and characterization of PEG-modified polyurethane pressure-sensitive adhesives for transdermal drug delivery *Drug Dev. Ind. Pharm.* **35** 704–11
- [212] Moon H T, Lee Y-K, Han J K and Byun Y 2001 A novel formulation for controlled release of heparin–DOCA conjugate dispersed as nanoparticles in polyurethane film *Biomaterials* **22** 281–9
- [213] Moura S A, Lima L D C, Andrade S P, Junior A D S-C, Órefice R L, Ayres E and Da Silva G R 2011 Local drug delivery system: inhibition of inflammatory angiogenesis in a murine sponge model by dexamethasone-loaded polyurethane implants *J. Pharm. Sci.* **100** 2886–95
- [214] Harisha R S, Hosamani K M, Keri R S, Shelke N, Wadi V K and Aminabhavi T M 2010 Controlled release of 5-fluorouracil from biomedical polyurethanes *Chem. Sci. J.* **122** 209–16
- [215] Basak P, Adhikari B, Banerjee I and Maiti T K 2009 Sustained release of antibiotic from polyurethane coated implant materials *J. Mater. Sci., Mater. Med.* **20** 213–21
- [216] Ring A, Goertz O, Muhr G, Steinau H U and Langer S 2008 *in vivo* microvascular response of murine cutaneous muscle to ibuprofen-releasing polyurethane foam *Int. Wound J.* **5** 464–9
- [217] Li B, Yoshii T, Hafeman A E, Nyman J S, Wenke J C and Guelcher S A 2009 The effects of rhBMP-2 released from biodegradable polyurethane/microsphere composite scaffolds on new bone formation in rat femora *Biomaterials* **30** 6768–79
- [218] Kenawy E-R, Al-Deyab S S and El-Newehy M H 2010 Controlled release of 5-Aminosalicylic acid (5-asa) from new biodegradable polyurethanes *Molecules* **15** 2257–68
- [219] Ghosh S and Mandal S M 2008 Novel Ibuprofen-based polyurethane: a new approach for drug delivery *J. Macromol. Sci. A* **45** 445–8
- [220] Simmons A, Padsalgikar A D, Ferris L M and Poole-Warren L A 2008 Biostability and biological performance of a PDMS-based polyurethane for controlled drug release *Biomaterials* **29** 2987–95
- [221] Da Silva G R, da Silva Cunha A, Ayres E and Oréface R L 2009 Effect of the macromolecular architecture of biodegradable polyurethanes on the controlled delivery of ocular drugs *J. Mater. Sci., Mater. Med.* **20** 481–7
- [222] Sivak W N, Zhang J, Petoud S and Beckman E J 2010 Incorporation of ionic ligands accelerates drug release from LDI-glycerol polyurethanes *Acta Biomater.* **6** 144–53
- [223] Sivak W N, Zhang J, Petoud S and Beckman E J 2010 Degradative-release as a function of drug structure from LDI-glycerol polyurethanes *Biomed. Mater. Eng.* **20** 269–81
- [224] Grigoreva M 2013 Polyurethane composites as drug carriers: release patterns *Biotechnol. Acta* **6** 041–8
- [225] Gentile P, Bellucci D, Sola A, Mattu C, Cannillo V and Ciardelli G 2015 Composite scaffolds for controlled drug release: role of the polyurethane nanoparticles on the physical properties and cell behaviour *J. Mech. Behav. Biomed. Mater.* **44** 53–60
- [226] Kolmas J, Sobczak M, Olędzka E, Nałęcz-Jawecki G and Dębek C 2014 Synthesis, characterization and *in vivo* evaluation of new composite bisphosphonate delivery systems *Int. J. Mol. Sci.* **15** 16831–47
- [227] Guo Q, Knight P T and Mather P T 2009 Tailored drug release from biodegradable stent coatings based on hybrid polyurethanes *J. Control. Release* **137** 224–33
- [228] Mattu C, Brachi G, Menichetti L, Flori A, Armanetti P, Ranzato E, Martinotti S, Nizzero S, Ferrari M and Ciardelli G 2018 Alternating block copolymer-based nanoparticles as tools to modulate the loading of multiple chemotherapeutics and imaging probes *Acta Biomater.* **80** 341–51
- [229] Basu A, Farah S, Kunduru K, Doppalapudi S, Khan W and Domb A 2016 Polyurethanes for controlled drug delivery *Advances in Polyurethane Biomaterials* (Woodhead Publishing) pp 217–46
- [230] Kohjiya S, Ikeda Y, Takesako S and Yamashita S 1991 Drug release behavior from polyurethane gel *React. Polym.* **15** 165–75
- [231] Yamaoka T, Makita Y, Sasatani H, Kim S-I and Kimura Y 2000 Linear type azo-containing polyurethane as drug-coating material for colon-specific delivery: its properties, degradation behavior, and utilization for drug formulation *J. Control. Release* **66** 187–97
- [232] Li B, Davidson J M and Guelcher S A 2009 The effect of the local delivery of platelet-derived growth factor from reactive two-component polyurethane scaffolds on the healing in rat skin excisional wounds *Biomaterials* **30** 3486–94

- [233] Crisante F, Francolini I, Bellusci M, Martinelli A, D'Ilario L and Piozzi A 2009 Antibiotic delivery polyurethanes containing albumin and polyallylamine nanoparticles *Eur. J. Pharm. Sci.* **36** 555–64
- [234] Sivak W N, Zhang J, Petoud S and Beckman E J 2009 Simultaneous drug release at different rates from biodegradable polyurethane foams *Acta Biomater.* **5** 2398–408
- [235] Johnson T J, Gupta K M, Fabian J, Albright T H and Kiser P F 2010 Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir *Eur. J. Pharm. Sci.* **39** 203–12
- [236] Huynh T T, Padois K, Sonvico F, Rossi A, Zani F, Pirot F, Doury J and Falson F 2010 Characterization of a polyurethane-based controlled release system for local delivery of chlorhexidine diacetate *Eur. J. Pharm. Biopharm.* **74** 255–64
- [237] Martinelli A, D'Ilario L, Francolini I and Piozzi A 2011 Water state effect on drug release from an antibiotic loaded polyurethane matrix containing albumin nanoparticles *Int. J. Pharm.* **407** 197–206
- [238] Sun X, Gao H, Wu G, Wang Y, Fan Y and Ma J 2011 Biodegradable and temperature-responsive polyurethanes for adriamycin delivery *Int. J. Pharm.* **412** 52–58
- [239] Shin M S, Hong J Y and Park S 2012 Gemcitabine release behavior of polyurethane matrixes designed for local anti-cancer drug delivery via stent *J. Drug Deliv. Sci. Technol.* **22** 301–6
- [240] Wang A, Gao H, Sun Y, Sun Y-L, Yang Y-W, Wu G, Wang Y, Fan Y and Ma J 2013 Temperature- and pH-responsive nanoparticles of biocompatible polyurethanes for doxorubicin delivery *Int. J. Pharm.* **441** 30–39
- [241] Claeys B, De Bruyn S, Hansen L, De Beer T, Remon J P and Vervaet C 2014 Release characteristics of polyurethane tablets containing dicarboxylic acids as release modifiers—a case study with diprophylline *Int. J. Pharm.* **477** 244–50
- [242] Claeys B, Vervaet C, Hillewaere X K, Possemiers S, Hansen L, De Beer T, Remon J P and Vervaet C 2015 Thermoplastic polyurethanes for the manufacturing of highly dosed oral sustained release matrices via hot melt extrusion and injection molding *Eur. J. Pharm. Biopharm.* **90** 44–52
- [243] Laurano R, Boffito M, Abrami M, Grassi M, Zoso A, Chiono V and Ciardelli G 2021 Dual stimuli-responsive polyurethane-based hydrogels as smart drug delivery carriers for the advanced treatment of chronic skin wounds *Bioact. Mater.* **6** 3013–24
- [244] Szczepańczyk P, Szlachta M, Złocista-Szewczyk N, Chłopek J and Pielichowska K 2021 Recent developments in polyurethane-based materials for bone tissue engineering *Polymers* **13** 946
- [245] Mo J Y, Leung N, Gupta P, Zhu B, Velliou E and Sui T 2021 Novel in situ multi-level analysis of structural-mechanical relations in a bioinspired polyurethane-based tissue model *Mater. Today Adv.* **12** 100184
- [246] Jaganathan S K, Mani M P, Rathanasamy R and Prabhakaran P 2018 Fabrication and characterization of tailor-made novel electrospun fibrous polyurethane scaffolds decorated with propolis and neem oil for tissue engineering applications *J. Ind. Text.* **49** 1178–97
- [247] Janik H and Marzec M 2015 A review: fabrication of porous polyurethane scaffolds *Mater. Sci. Eng. C* **48** 586–91
- [248] Fathi-Karkan S, Banimohamad-Shotorbani B, Saghati S, Rahbarghazi R and Davaran S 2022 A critical review of fibrous polyurethane-based vascular tissue engineering scaffolds *J. Biol. Eng.* **16** 6
- [249] Luo K, Wang L, Chen X, Zeng X, Zhou S, Zhang P and Li J 2020 Biomimetic polyurethane 3D scaffolds based on polytetrahydrofuran glycol and polyethylene glycol for soft tissue engineering *Polymers* **12** 2631
- [250] Haugen H, Will J, Fuchs W and Wintermantel E 2006 A novel processing method for injection-molded polyether-urethane scaffolds. Part 1: processing *J. Biomed. Mater. Res. B* **77** 65–72
- [251] Kucinska-Lipka J, Gubanska I, Janik H and Sienkiewicz M 2015 Fabrication of polyurethane and polyurethane based composite fibres by the electrospinning technique for soft tissue engineering of cardiovascular system *Mater. Sci. Eng. C* **46** 166–76
- [252] Rekabgardan M, Parandakh A, Shahriari S, Koochpar Z K, Rahmani M, Ganjouri C, Sarbandi R R and Khani M-M 2022 An electrospun PGS/PU fibrous scaffold to support and promote endothelial differentiation of mesenchymal stem cells under dynamic culture condition *J. Drug Deliv. Sci. Technol.* **72** 103383
- [253] Sin D, Miao X G, Liu G, Wei F, Chadwick G, Yan C and Friis T 2010 Polyurethane (PU) scaffolds prepared by solvent casting/particulate leaching (SCPL) combined with centrifugation *Mater. Sci. Eng. C* **30** 78–85
- [254] Ali A, Ul Amin B, Yu W, Gui T, Cong W, Zhang K, Tong Z, Hu J, Zhan X and Zhang Q 2023 Eco-friendly biodegradable polyurethane based coating for antibacterial and antifouling performance *Chin. J. Chem. Eng.* **54** 80–88
- [255] Jothi K J, Balachandran S, Mohanraj K, Prakash N, Subhasri A, Gopala Krishnan P S and Palanivelu K 2022 Fabrications of hybrid polyurethane-Pd doped ZrO(2) smart carriers for self-healing high corrosion protective coatings *Environ. Res.* **211** 113095
- [256] Sheikholeslam M, Wright M E, Cheng N, Oh H H, Wang Y, Datu A K, Santerre J P, Amini-Nik S and Jeschke M G 2019 Electrospun polyurethane–gelatin composite: a new tissue-engineered scaffold for application in skin regeneration and repair of complex wounds *ACS Biomater. Sci. Eng.* **6** 505–16
- [257] Davis K A, Burke K A, Mather P T and Henderson J H 2011 Dynamic cell behavior on shape memory polymer substrates *Biomaterials* **32** 2285–93
- [258] Bao M, Lou X, Zhou Q, Dong W, Yuan H and Zhang Y 2014 Electrospun biomimetic fibrous scaffold from shape memory polymer of PDLLA-co-TMC for bone tissue engineering *ACS Appl. Mater. Interfaces* **6** 2611–21
- [259] Kucinska-Lipka J, Gubanska I, Strankowski M, Cieśliński H, Filipowicz N and Janik H 2017 Synthesis and characterization of cycloaliphatic hydrophilic polyurethanes, modified with L-ascorbic acid, as materials for soft tissue regeneration *Mater. Sci. Eng. C* **75** 671–81
- [260] Shahrousvand M, Hoseinian M S, Ghollasi M, Karbalaieimahdi A, Salimi A and Tabar F A 2017 Flexible magnetic polyurethane/Fe₂O₃ nanoparticles as organic-inorganic nanocomposites for biomedical applications: properties and cell behavior *Mater. Sci. Eng. C* **74** 556–67
- [261] Li L, Zuo Y, Zou Q, Yang B, Lin L, Li J and Li Y 2015 Hierarchical structure and mechanical improvement of an n-HA/GCO–PU composite scaffold for bone regeneration *ACS Appl. Mater. Interfaces* **40** 22618–29
- [262] Sultan M 2018 Hydroxyapatite/polyurethane composites as promising biomaterials *Chem. Pap.* **72** 2375–95
- [263] Przybytek A, Gubańska I, Kucińska-Lipka J and Janik H 2018 Polyurethanes as a potential medical-grade filament for use in fused deposition modeling 3D printers—a brief review *Fibres Text. East. Eur.* **132** 120–5
- [264] Piotrowska-Kirschling A and Brzeska J 2020 The effect of chitosan on the chemical structure, morphology, and selected properties of polyurethane/chitosan composites *Polymers* **12** 1205
- [265] Zuber M, Zia F, Zia K M, Tabasum S, Salman M and Sultan N 2015 Collagen based polyurethanes—a review of recent advances and perspective *Int. J. Biol. Macromol.* **80** 366–74
- [266] Mehrban N, Bowen J, Tait A, Darbyshire A, Virasami A K, Lowdell M W and Birchall M A 2018 Silsesquioxane polymer as a potential scaffold for laryngeal reconstruction *Mater. Sci. Eng. C* **92** 565–74

- [267] Wismayer K, Mehrban N, Bowen J and Birchall M 2019 Improving cellular migration in tissue-engineered laryngeal scaffolds *J. Laryngol. Otol.* **133** 135–48
- [268] Sartori S, Chiono V, Tonda-Turo C, Mattu C and Gianluca C 2014 Biomimetic polyurethanes in nano and regenerative medicine *J. Mater. Chem. B* **2** 5128–44
- [269] Jaganathan S K, Mani M P and Supriyanto E 2019 Blood compatibility assessments of electrospun polyurethane nanocomposites blended with megni oil for tissue engineering applications *An. Acad. Bras. Cienc.* **91** e20190018
- [270] Tawagi E, Ganesh T, Cheng H-L M and Santerre J P 2019 Synthesis of degradable-polar-hydrophobic-ionic co-polymeric microspheres by membrane emulsion photopolymerization: *in vitro* and *in vivo* studies *Acta Biomater.* **89** 279–88
- [271] Shokraei N, Asadpour S, Shokraei S, Nasrollahzadeh Sabet M, Faridi-Majidi R and Ghanbari H 2019 Development of electrically conductive hybrid nanofibers based on CNT-polyurethane nanocomposite for cardiac tissue engineering *Microsc. Res. Tech.* **82** 1316–25
- [272] Yuan Y, Basu S, Lin M H, Shukla S and Sarkar D 2019 Colloidal gels for guiding endothelial cell organization via microstructural morphology *ACS Appl. Mater. Interfaces* **11** 31709–28
- [273] Zhang H, Q-w F, Sun T-W, Chen F, Qi C, Wu J, Cai Z-Y, Qian Q-R and Zhu Y-J 2015 Amorphous calcium phosphate, hydroxyapatite and poly (D, L-lactic acid) composite nanofibers: electrospinning preparation, mineralization and *in vivo* bone defect repair *Colloids Surf. B* **136** 27–36
- [274] Watcharajittanont N, Putson C, Pripatanont P and Meesane J 2019 Layer-by-layer electrospun membranes of polyurethane/silk fibroin based on mimicking of oral soft tissue for guided bone regeneration *Biomed. Mater.* **14** 055011
- [275] Chung S and Webster T 2016 Antimicrobial nanostructured polyurethane scaffolds *Advances in Polyurethane Biomaterials* (Woodhead Publishing)
- [276] Naureen B, Haseeb A S M A, Basirun W J and Muhamad F 2021 Recent advances in tissue engineering scaffolds based on polyurethane and modified polyurethane *Mater. Sci. Eng. C* **118** 111228
- [277] Harding K, Morris H and Patel G 2002 Clinical review Healing chronic wounds *Br. Med. J.* **324** 160–3
- [278] Rezvani Ghomi E, Khalili S, Nouri Khorasani S, Esmaeely Neisiany R and Ramakrishna S 2019 Wound dressings: current advances and future directions *J. Appl. Polym. Sci.* **136** 47738
- [279] Tan L, Hu J, Huang H, Han J and Hu H 2015 Study of multi-functional electrospun composite nanofibrous mats for smart wound healing *Int. J. Biol. Macromol.* **79** 469–76
- [280] Lin Y-J, Lee G-H, Chou C-W, Chen Y-P, T-h W and Lin H-R 2015 Stimulation of wound healing by PU/hydrogel composites containing fibroblast growth factor-2 *J. Mater. Chem. B* **3** 1931–41
- [281] Triller C, Huljev D and Smrke D 2012 Application of modern wound dressings in the treatment of chronic wounds *Acta Med. Croat.* **66** 65–69
- [282] Eskandarinia A, Kefayat A, Gharakhloo M, Agheb M, Khodabakhshi D, Khorshidi M, Sheikmoradi V, Rafienia M and Salehi H 2020 A propolis enriched polyurethane-hyaluronic acid nanofibrous wound dressing with remarkable antibacterial and wound healing activities *Int. J. Biol. Macromol.* **149** 467–76
- [283] Li S et al 2022 Antimicrobial lignin-based polyurethane/Ag composite foams for improving wound healing *Biomacromolecules* **23** 1622–32
- [284] Jaganathan S K and Mani M P 2018 Electrospun polyurethane nanofibrous composite impregnated with metallic copper for wound-healing application *3 Biotech* **8** 1–12
- [285] Li M, Chen J, Shi M, Zhang H, Ma P X and Guo B 2019 Electroactive anti-oxidant polyurethane elastomers with shape memory property as non-adherent wound dressing to enhance wound healing *J. Chem. Eng.* **375** 121999
- [286] Di Mario C, Kilic I D, Yeh J S, Pighi M, Serdoz R, Gatzoulis M A and Dimopoulos K 2015 Exclusion of a giant aneurysm post-Kawasaki disease with novel polyurethane covered stents *Int. J. Cardiol.* **184** 664–6
- [287] Song E-H, Jeong S-H, Park J-U, Kim S, Kim H-E and Song J 2017 Polyurethane-silica hybrid foams from a one-step foaming reaction, coupled with a sol-gel process, for enhanced wound healing *Mater. Sci. Eng. C* **79** 866–74
- [288] Shin E J and Choi S M 2018 Advances in waterborne polyurethane-based biomaterials for biomedical applications *Novel Biomaterials for Regenerative Medicine (Advances in Experimental Medicine and Biology)* ed H Chun, K Park, C H Kim and G Khang (Springer)
- [289] Li J R, Chang H E, Zhang N, He Y Z, Zhang D and Liu B S and Fang Y 2023 Recent advances in enzyme inhibition based-electrochemical biosensors for pharmaceutical and environmental analysis *Talanta* **253** 124092
- [290] Saxena S and Katara D P 2022 3D-printed device with integrated biosensors for biomedical applications *Biosensor Based Advanced Cancer Diagnostics* ed R Khan, A Parihar and S K Sanghi (Academic)
- [291] Mohankumar P, Ajayan J, Mohanraj T and Yasodharan R 2021 Recent developments in biosensors for healthcare and biomedical applications: a review *Measurement* **167** 108293
- [292] Sun C, Niu Y, Tong F Y, Mao C, Huang X H, Zhao B and Shen J 2013 Preparation of novel electrochemical glucose biosensors for whole blood based on antibiofouling polyurethane-heparin nanoparticles *Electrochim. Acta* **97** 349–56
- [293] Jin X, Li G, Xu T, Su L, Yan D and Zhang X 2022 Fully integrated flexible biosensor for wearable continuous glucose monitoring *Biosens. Bioelectron.* **196** 113760
- [294] Bhattacharjee A, Clark R, Gentry-Weeks C and Li Y V 2020 A novel receptor-free polydiacetylene nanofiber biosensor for detecting *E. coli* via colorimetric changes *Mater. Adv.* **1** 3387–97
- [295] Nejadmansouri M, Majdinasab M, Nunes G S and Marty J L 2021 An overview of optical and electrochemical sensors and biosensors for analysis of antioxidants in food during the last 5 years *Sensors* **21** 1176
- [296] Alhadrami H A 2018 Biosensors: classifications ma, and future prospective *Biotechnol. Appl. Biochem.* **65** 497–508
- [297] Yu B, Moussy Y and Moussy F 2005 Coil-type implantable glucose biosensor with excess enzyme loading *Front. Biosci. Landmark* **10** 512–20
- [298] Han J H, Taylor J D, Kim D S, Kim Y S, Kim Y T, Cha G S and Nam H 2007 Glucose biosensor with a hydrophilic polyurethane (HPU) blended with polyvinyl alcohol/vinyl butyral copolymer (PVAB) outer membrane *Sens. Actuators B* **123** 384–90
- [299] Wang N, Burugapalli K, Song W, Halls J, Moussy F, Ray A and Zheng Y 2013 Electrospun fibro-porous polyurethane coatings for implantable glucose biosensors *Biomaterials* **34** 888–901
- [300] Wang M et al 2015 Enteric polymer based on pH-responsive aliphatic polycarbonate functionalized with vitamin E to facilitate oral delivery of tacrolimus *Biomacromolecules* **16** 1179–90
- [301] Nabid M R and Omrani I 2016 Facile preparation of pH-responsive polyurethane nanocarrier for oral delivery *Mater. Sci. Eng. C* **69** 532–7

- [302] Veloso-Fernández A, Laza J M, Ruiz-Rubio L, Martín A, Taguado M, Benito-Vicente A, Martín C and Vilas J L 2022 Towards a new generation of non-cytotoxic shape memory thermoplastic polyurethanes for biomedical applications *Mater. Today Commun.* **33** 104730
- [303] Padsalgikar A D (ed) 2022 Chemistry of polyurethane materials *Applications of Polyurethanes in Medical Devices* (William Andrew Publishing) pp 9–41
- [304] Shah D and Chowdhury M M 2011 Rubber allergy *Clin. Dermatol.* **29** 278–86
- [305] Brookstein D S 2009 Factors associated with textile pattern dermatitis caused by contact allergy to dyes f, foams, and preservatives *Dermatol. Clin.* **27** 309–22
- [306] Neumann W, Pusch T P, Siegfarth M, Schad L R and Stallkamp J L 2019 CT and MRI compatibility of flexible 3D-printed materials for soft actuators and robots used in image-guided interventions *Med. Phys.* **46** 5488–98
- [307] Bertoldi S, Fare S, Haugen H J and Tanzi M C 2015 Exploiting novel sterilization techniques for porous polyurethane scaffolds *J. Mater. Sci., Mater. Med.* **26** 182